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In general, iron represents a double-edged sword in metabolism in most tissues,
especially in the brain. Although the high metabolic demands of brain cells require
iron as a redox-active metal for ATP-producing enzymes, the brain is highly vulnerable
to the devastating consequences of excessive iron-induced oxidative stress and, as
recently found, to ferroptosis as well. The blood–brain barrier (BBB) protects the brain
from fluctuations in systemic iron. Under pathological conditions, especially in acute
brain pathologies such as stroke, the BBB is disrupted, and iron pools from the blood
gain sudden access to the brain parenchyma, which is crucial in mediating stroke-
induced neurodegeneration. Each brain cell type reacts with changes in their expression
of proteins involved in iron uptake, efflux, storage, and mobilization to preserve its
internal iron homeostasis, with specific organelles such as mitochondria showing
specialized responses. However, during ischemia, neurons are challenged with excess
extracellular glutamate in the presence of high levels of extracellular iron; this causes
glutamate receptor overactivation that boosts neuronal iron uptake and a subsequent
overproduction of membrane peroxides. This glutamate-driven neuronal death can be
attenuated by iron-chelating compounds or free radical scavenger molecules. Moreover,
vascular wall rupture in hemorrhagic stroke results in the accumulation and lysis of
iron-rich red blood cells at the brain parenchyma and the subsequent presence of
hemoglobin and heme iron at the extracellular milieu, thereby contributing to iron-
induced lipid peroxidation and cell death. This review summarizes recent progresses
made in understanding the ferroptosis component underlying both ischemic and
hemorrhagic stroke subtypes.
Keywords: iron, reactive oxygen species, ferroptosis, stroke, excitotoxicity, iron dyshomeostasis,
neurodegeneration, transferrin saturation
Abbreviations: AIS, acute ischemic stroke; ALOX5: arachidonic acid lipoxygenase 5; APP, amyloid precursor protein;
BBB, brain–blood barrier; CSF, cerebrospinal fluid; Dexras1, dexamethasone-induced Ras protein 1; DFO, deferoxamine;
DMT1, divalent metal transporter 1; EAATs, excitatory amino acid transporters; FPN, ferroportin; FT, ferritin; FTH, ferritin
heavy chain; GAPDH, glyceraldehyde-3-phosphate dehydrogenase; GPX4, glutathione peroxidase 4; GSH, glutathione; Hb,
hemoglobin; HO, heme oxygenase; Hp, haptoglobin; Hpx, hemopexin; HTf, holotransferrin; ICH, intracerebral hemorrhage;
I/R, ischemia/reperfusion; IREs, iron regulatory elements; IRPs, iron regulatory proteins; NAC, N-acetylcysteine; NMDA,
N-methyl-D-aspartate; NTBI, non-transferrin-bound iron; OGD, oxygen and glucose deprivation; PUFA, polyunsaturated
fatty acids; ROS, reactive oxygen species; TIM, T-cell immunoglobulin and mucin domain-containing receptor; Tf,
transferrin; TfR1, transferrin receptor 1; TfR2, transferrin receptor 2; TSAT, saturation of transferrin with iron; UTRs,
untranslated regions; X−c , cystine/glutamate exchanger or antiporter, i.e., SLC7A11/xCT.
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IRON TRANSPORT TO THE BRAIN: THE
ROLE OF THE BLOOD–BRAIN BARRIER
Iron is essential for life; numerous proteins require iron as a
cofactor for their activity. Iron acts as an electron donor or
acceptor, and thus is pivotal for oxygen transport (coordinated
with hemoglobin), cellular respiration (as a part of heme-
containing cytochromes and proteins containing Fe–S groups in
the electron transport chain), and DNA synthesis (in ribonuclease
reductase). Moreover, in the nervous system, iron is essential for
myelinization and neurotransmitter biosynthesis.
Iron exists both as Fe2+ and Fe3+; redox-active and cycling
between these two states lead to the generation of reactive
oxygen species (ROS) through the Fenton reaction. The ROS
promote oxidative stress and cause extensive lipid peroxidation
(Gutteridge et al., 1979). The brain is particularly vulnerable to
lipid peroxidation damage because it is rich in polyunsaturated
fatty acids (PUFAs) and iron, but relatively poor in antioxidant
defenses (Cobley et al., 2018). The iron content remarkably
differs across different brain regions: it is high in the striatum,
medium in the hippocampus and cortex, and low in the pons and
medulla (Ramos et al., 2014). Although it has recently attracted
considerable attention, iron metabolism in the brain is yet not
completely understood as that in other murine tissues (Ashraf
et al., 2018). Brain imports iron from systemic circulation, and the
levels of iron are determined by diet, intestinal iron absorption,
release of iron initially stored in the hepatocytes, and export
of iron recycled from macrophages. In addition, the levels of
iron in the plasma are regulated by the hormone hepcidin
through its effect on the transmembrane iron export protein
ferroportin (FPN), which is mainly present at the cell membrane
of macrophages, hepatocytes, and enterocytes.
In the blood and most other extracellular fluids, iron is
essentially carried bound with high affinity to the iron transport
protein transferrin (Tf), which shields Fe3+ from redox activity.
In addition to Tf, iron also associates with other carrier proteins
in the blood such as ferritin (FT), haptoglobin (Hp), Hpx, or
albumin. Recently, half a dozen different non-proteinaceous low-
molecular-weight iron species (<10 KDa) have been shown to
exist in the blood (Dziuba and Lindahl, 2018); further studies
are required to determine the precise identity and physiological
role of these species. Once iron is bound to Tf, Fe3+ is rendered
redox-inactive and virtually non-exchangeable or displaceable
by other physiological metals or molecules. Tf−iron complexes
circulate in the blood until they bind transferrin receptors (TfRs)
in cellular membranes of target cells. In general, in non-iron-
overload conditions, little, if any, non-transferrin-bound iron
(NTBI) is found in the blood of healthy individuals (Gaasch et al.,
2007). The high affinity of Tf for iron and the large amount of
Tf in the blood exceed the total requirement for iron binding;
in normal human blood, the saturation of transferrin with iron
(TSAT) is only of around 30% (De Valk et al., 2000; Van Dijk
et al., 2008). Therefore, iron transport to the brain is mainly
from iron-loaded transferrin (holotransferrin, HTf) through the
endothelial cells of the BBB and the epithelium of the choroid
plexuses and arachnoid membrane, the blood–cerebrospinal fluid
(CSF) barrier.
Although barrier cells of the brain form tight junctions
laterally, epithelial cells of the choroid plexuses are fenestrated
and more permeable than the endothelial cells of the BBB
(Strazielle and Ghersi-Egea, 2016). The abluminal side of
brain capillary endothelial cells is surrounded by pericytes and
astrocytes of the neurovascular unit that provide extra structural
and functional support. TfRs are abundantly expressed in the
luminal side of membranes of polarized endothelial cells; once
they bind Tf, the TfR–Tf complexes undergo endocytosis. The
following steps are still controversial, and different pathways
are thought to be involved in brain iron acquisition (Bradbury,
1997; Khan et al., 2018). Thus far, the main contribution to
this process is thought to include the following pathways: (1)
endocytic vesicles containing TfR–HTf traveling from the luminal
membrane to fuse to the abluminal membrane and exocytose
either HTf or free iron into the brain extracellular space; (2) under
low pH conditions within the endosome of endothelial cells, as
in most cell types, iron is extracted from Tf, converted to Fe2+
by endosomal ferrireductases such as the six-transmembrane
epithelial antigen of prostate protein 3 (Steap3), and released
to the cytosol through divalent metal transporter 1 (DMT1)
or the ion channels TRPML, also known as mucolipin 1 or
MCOLN1 (detailed information can be found in references
Luck and Mason, 2012; Skjorringe et al., 2015). Subsequently,
Fe2+ from the cytosol is exported through FPN present in the
abluminal membrane of endothelial cells, which are in contact
with astrocytes expressing ceruloplasmin, that rapidly oxidize
Fe2+ to Fe3+ (this Tf/TfR endocytosis mechanism is common
for endothelial and neuronal cells and is depicted in Figures 1,
2). A recent study performed using comprehensive mathematical
models concluded that optimal iron homeostasis is dependent on
the degree of saturation and the transport of HTf across the BBB
from the blood (Khan et al., 2018).
In addition, in mice exposed to experimental stroke under
normal iron conditions, iron deposits in the microvasculature
were observed early in the border zone of the damaged areas
(Desestret et al., 2009), suggesting that, when signaled, the BBB
might function as an iron reservoir from which iron is released
into the brain. Regarding signaling to release, in bovine retinal
endothelial cells, the FPN-mediated iron export is known to
be blocked by the FPN inhibitor hepcidin (Hadziahmetovic
et al., 2011). In addition, new insights into the communication
between systemic iron status and brain iron uptake reveal
the regulation of brain iron uptake at the level of brain
microvascular endothelial cells rather than the BBB acting merely
as a retaining wall (Chiou et al., 2018b). In support of this
regulatory hypothesis, endothelial microvascular cell distribution
of TfR is altered in luminal, intracellular, and abluminal
membranes depending on brain iron status (Simpson et al.,
2015), and microvascular cell iron availability and efflux have
been found to be tightly modulated by diffusible ceruloplasmin
and hepcidin released from astrocytes surrounding the BBB
(McCarthy and Kosman, 2014). Moreover, a recent study showed
that inhibition of DMT1 alters the transport of iron and Tf
across the endothelial cells and proposed that the levels of iron-
devoid Tf (apotransferrin) and iron delivered to the brain are
strongly regulated by the ratio apotransferrin:HTf as well as by
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FIGURE 1 | Schematic drawing of some of the main players in iron transport to the brain in control (left hand upper side), iron overload (right-hand upper side),
ischemic stroke (left-hand lower side), or intracerebral hemorrhage (right-hand lower side). The thicker the arrows the more increased the transport. Abbreviations:
ATf, apotransferrin; FPN, ferroportin; HTf, holotransferrin; FT, ferritin, GPX4, glutathione peroxidase 4; GSH, glutathione; Hb, hemoglobin; NTBI,
non-transferrin-bound iron; ROS, reactive oxygen species; TJ, tight junction; ZA, zonula occludens.
hepcidin levels in the extracellular fluid of each brain region
(Duck et al., 2017).
Further, very recently, a new function for FT heavy chain
(FTH) as a transporter of NTBI across the BBB by binding
to the T-cell immunoglobulin and mucin domain-containing 1
receptor 1 (TIM-1) has been reported in human endothelial cells
(Chiou et al., 2018b).
In the context of physiological iron-overload conditions
found, for instance, in individuals on iron-rich diets, a significant
pool of NTBI is found in the blood and might be readily absorbed
by microvascular endothelial cells. This effect might be relevant
considering that regional differences in the brain uptake of
59Fe–NTBI versus 59Fe–TfR have been reported (Deane et al.,
2004), and that 59Fe–NTBI seems to be transported faster than
59Fe–TfR into the brain parenchyma of iron-overloaded disease-
free mice. Furthermore, the iron storage protein FT has been
found to be upregulated in epithelial cells of the choroid plexus
and endothelial cells of the brain during systemic iron overload
(Tripathi et al., 2017).
IRON UPTAKE AND HANDLING BY
PARENCHYMAL BRAIN CELLS
Once in the brain interstitial fluid, both TBI and NTBI are
potential iron sources for brain cells (Gaasch et al., 2007); unlike
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FIGURE 2 | Schematic drawing of some of the main players in a neuron under ischemic (left-hand side) and hemorrhagic (right-hand side) stress (see text for
details). Abbreviations: APP, amyloid precursor protein; ATf, apotransferrin; CD163, hemoglobin/haptoglobin receptor; CD91, heme/hemopexin receptor; CO,
carbon monoxide; CP, ceruloplasmin; DMT1, divalent metal transporter 1; EAAT, excitatory amino acid transporter; Fe2+, ferrous iron; Fe3+, ferric iron; Fe–S,
iron–sulfur cluster; FPN, ferroportin; FT, ferritin; GAPDH, glyceraldehyde-3-phosphate dehydrogenase; GLS, glutaminase; GPX4, glutathione peroxidase 4; GSH,
glutathione; GSSG, glutathione disulfide; Hb, hemoglobin; HFE, hereditary hemochromatosis protein; HIF, hypoxia-inducible factor; HO1, heme oxygenase 1; Hp,
haptoglobin; Hpx, hemopexin; HTf, holotransferrin; IRE, iron-responsive element; IRPs, iron regulatory proteins; LIP, labile iron pool; MCOLN1, mucolipin 1; MtFT,
mitochondrial ferritin; NCOA, nuclear receptor coactivator; NMDAR, NMDA receptor; NTBI, non-transferrin-bound iron; OH, hydroxyl radical; PCBP, poly(rC)-binding
protein; PUFA, poly-unsaturated fatty acid; PUFA-OOH, PUFA peroxide; ROS, reactive oxygen species; Se, selenium; Steap, six-transmembrane epithelial antigen of
prostate; system X−c , cystine–glutamate antiporter; TfR1, transferrin receptor 1; TfR2, transferrin receptor 2; ZIP8/14, zinc transporters 8/14. The picture depicts the
effect of one of the major players in the pathophysiology of brain I, the disruption of glutamatergic neurotransmission homeostasis that produces elevated
extracellular glutamate levels, overactivation of the NMDA subtype of glutamate receptors (NMDAR), and excitotoxic cell death. In the recent past, different authors
have shown that this NMDAR overactivation boosts neuronal iron uptake and produces an iron-dependent form of neuronal death associated with massive lipid
peroxidation that fits with the definition of ferroptosis. Further, in the hemorrhage type of stroke, iron derived from hemoglobin and/or heme enters neurons and
produces massive lipid peroxidation. Damage by ischemic and hemorrhagic stroke is alleviated by the inhibitors of ferroptosis.
blood Tf, CSF Tf is considered to be completely saturated with
iron (Bradbury, 1997). Within the extracellular milieu of the
brain parenchyma, iron is carried loaded into Tf or bound to
low-molecular-weight molecules such as citrate, ascorbate, or
ATP. Each brain cell type uptakes extracellular TBI or NTBI
depending on the iron-transport receptors and channels present
in their membranes and, physiologically, safely handles iron by
using the network of proteins they specifically express to import,
store, traffic, and export iron. Players of cellular iron homeostasis
are cell type-specific, and the list of proteins involved in iron
homeostasis is still growing. As an example of iron-related new
proteins, only 3 years ago, the members of the ZIP family of
metal ion transporters Zip8 and Zip14, which, unlike the DMT1
transporter are only active at normal physiological pH, were
reported to be expressed by hippocampal neurons, and Zip8 was
found to play a major role in the accumulation of NTBI by
hippocampal neurons (Ji and Kosman, 2015), whereas both Zip8
and Zip14 were considered to play a role in iron homeostasis in
rat retina (Sterling et al., 2017).
Receptors Involved in Iron Uptake by
Brain Cells
In addition to the well-known TfR1 as a main player of the
TfR/Tf endocytic pathway in most brain cells, other proteins, e.g.,
transferrin receptor 2 (TfR2) (Kawabata, 2018) or glyceraldehyde-
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3-phosphate dehydrogenase (GAPDH) (Raje et al., 2007), have
been described as receptors for Tf and are currently being
investigated. TfR1 binds HTf with a Kd of 1 nM; it is expressed
in response to changes in iron levels through modulation by
iron regulatory elements (IREs) present in its mRNA and
binds hereditary hemochromatosis HFE protein, a molecule that
competes with HTf for binding to TfR1. In contrast, TfR2 has
lower affinity for HTf; its levels are not modulated by IREs (West
et al., 2000) and, although still controversial, seems to bind HFE
protein in a sequence non-overlapping to that of the Tf-binding
site (for a review see Worthen and Enns, 2014).
The TfR2 is present in two main isoforms, TfR2α and TfR2β.
The TfR2α form has been reported to be more abundant in the
brain, especially in the hippocampus; brain TfR2α levels were
reported to significantly differ across animals fed iron-deficient
or iron-enriched diets (Pellegrino et al., 2016). A specific role
for TfR2 in the control of the iron regulatory network in the
brain tissue has been recently suggested, as altered brain IRPs,
iron accumulation, and reactive microglia signaling were found
in TfR2-KO mice (Pellegrino et al., 2016). In contrast, a previous
study on TfR2 mutant mice showed changes in hepatic, but not
brain iron levels, although that study reported a 30% increase in
brain FT levels (Acikyol et al., 2013).
In addition to TfR1 and TfR2, the multifunctional molecule
GAPDH has been reported to work as a TfR in different cell
types (Raje et al., 2007; Kumar et al., 2012) with a role in iron
uptake and/or iron export (Sheokand et al., 2016) and as a
chaperone for intracellular heme traffic (Sweeny et al., 2018).
Relevant to brain and excitotoxicity, GAPDH interacts with the
α-amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid subtype
of glutamate receptors in the neurons without glutamate
stimulation and has also been reported to be pivotal for axon
development (Lee et al., 2016).
Another receptor-mediated means to import iron into brain
cells, at least in oligodendrocytes, is the uptake of FTH through
TIM-1/2 receptors (Todorich et al., 2008, 2011; Chiou et al.,
2018a). In other non-neuronal cells, FTH internalize through
TfR1 (Li et al., 2010), whereas scavenger receptor class A member
5 (SCARA5) has been found to play also a role as a receptor
for FT light chain uptake (Li et al., 2009). To the best of our
knowledge, the role of SCARA5 has not yet been investigated in
any brain cell type.
Mechanisms and Proteins Involved in
Cytosolic Iron Handling in Different Brain
Cell Types
Inside the cell cytosolic and nuclear compartments, iron
chaperone poly(rC)-binding proteins serve the binding and
delivery of iron to iron-requiring enzymes, ubiquitous protein
of iron storage FT, or the iron export membrane protein FPN
(Philpott et al., 2017). In the cytosol, unused iron is stored
into FT, a molecule composed of 24 subunits of a variable
proportion of heavy and light chains, that shields up to 4500
iron atoms in a redox inert state. Neurons express both TfR1
and DMT1 (Pelizzoni et al., 2012; DeGregorio-Rocasolano et al.,
2018); DMT1 is mainly found in the cytoplasm colocalizing
with endosomes/lysosomes. Further, neurons express the iron
export molecule FPN (Burdo et al., 2001; Zhou et al., 2017).
Astrocytes express TfR1, DMT1, and FPN (Yang et al., 2012;
Huang et al., 2014). Hence, although TfR1 is considered to be
the main gate for cellular iron import, control astrocytes show
low TfR1 levels, and most mature oligodendrocytes or microglial
cells do not express TfR1 (Kaur and Ling, 1995; Rathnasamy
et al., 2016). However, under hypoxia, both astrocytes and
oligodendrocytes are found to upregulate TfR (Yang et al., 2012;
Rathnasamy et al., 2016). Moreover, oligodendrocytes and cells of
choroid plexuses, but not other brain cell types, express Tf under
normal condition (Leitner and Connor, 2012). All the above
are examples of the important heterogeneity in the expression
and induction of iron homeostatic or IRPs observed in different
brain cell types and situations. Most of the proteins involved
in iron metabolism, including cytosolic FT levels, are mainly
regulated by iron, oxidative stress, and inflammation. The iron-
dependent regulation occurs mainly at the post-transcriptional
level via the IREs and iron regulatory protein (IRP) machinery.
When iron levels are high, iron binds to the IRP, which then
loses affinity for the IRE sequence in FT mRNA, resulting in
increased FT expression (the cytosolic iron handling is depicted
in Figure 2) (Arosio et al., 2017). Several studies have shown
that the mobilization of iron from FT requires FT degradation
either by lysosome–autophagy or ubiquitin proteasome pathways
(Asano et al., 2011; Mancias et al., 2015). In addition to its role
in storing iron within the cell, FT can be secreted (Truman-
Rosentsvit et al., 2018).
In addition to post-transcriptional regulation, transcriptional
regulation has been reported for some of the proteins involved
in iron homeostasis through the hypoxia-inducible factor family
of transcription factors or the heme-dependent transcription
factors (e.g., for TfR1 or FPN) (Marro et al., 2010; Man-man et al.,
2017). Moreover, the master regulator of bodily iron homeostasis
hepcidin is subjected to a sophisticated transcriptional regulation
through the bone morphogenetic protein/SMAD pathway,
interleukin 6 pathway, or erythropoietin/erythroferrone
pathways when regulated according to the iron, inflammatory,
or erythropoietic demands (Sangkhae and Nemeth, 2017). The
regulation of cellular iron balance has been recently reviewed
(Recalcati et al., 2017).
Iron also plays an important role in specific organelles; this
is especially true for mitochondria. Mitochondria house the
assembly of heme, the majority of the Fe–S cluster biosynthesis
apparatus, and contain the respiratory complexes that need iron-
containing cofactors. In addition, mitochondria are a major
source of endogenous ROS. Sustained iron exposure increased
mitochondrial ROS levels in dopaminergic neuroblastoma SH-
SY5Y cells (Huang et al., 2017), and scavenging of mitochondrial
ROS was protective against iron overload damage in hippocampal
neurons, preserving mitochondrial morphological integrity and
membrane potential (Pelizzoni et al., 2011). In addition, a recent
study showed that sequestration of iron by mitochondrial FT was
neuroprotective against oxidative stress and played an important
role in preventing neuronal damage in some other conditions
(You et al., 2016; Guan et al., 2017). Moreover, mitochondrial
FT overexpression significantly reduced cellular labile iron pool,
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prevented H2O2-induced elevation of labile iron, and rescued
cells from H2O2-induced damage (Gao et al., 2017).
In several cell types, although not yet studied in neurons,
mitochondria−endosome interactions have been observed,
suggesting a possible direct transfer of iron from endosomes to
mitochondria (Das et al., 2016; Hamdi et al., 2016) through the
“kiss-and-run” hypothesis.
IRON DYSHOMEOSTASIS IN THE BRAIN
Brain iron abnormalities are associated to rare, but severe,
neurodegenerative conditions, and there is growing evidence
that the more common systemic iron overload disorders such
as hereditary hemochromatosis exert important effects on the
brain iron content and pathological brain iron deposition
(Nandar and Connor, 2011; Kumar et al., 2016). Moreover, the
hemochromatosis H63D polymorphism of the HFE gene could be
a disease-modifying gene in frontotemporal lobar degeneration,
fostering iron deposition in the basal ganglia (Gazzina et al.,
2016), or even macro- and microanatomically altering some
brain structures associated with changes in Tf levels in the
blood (Jahanshad et al., 2012). Recently, abnormal recycling
of TfR1 due to reduced post-translational palmitoylation has
been reported to be crucial to affect the iron import in the so-
called neurodegeneration with brain iron accumulation disease
(Drecourt et al., 2018). Further, neurodegeneration with brain
iron accumulation disease-linked genes that showed altered
expression in response to iron loading has been recently
reported to be directly or indirectly related to myelin metabolism
(Heidari et al., 2016).
A list of mild conditions, including aging (Ward et al.,
2014), continuous uptake of some bioavailable iron sources
(Peters et al., 2018), or obesity (Han et al., 2017), have been
reported to alter brain iron content and/or distribution. In
addition, a recent report showed that iron administration
increases iron levels in the brains of healthy rats, which induces
brain changes and triggers a hormetic response that reduces
oxidative damage (Piloni et al., 2018). Moreover, other studies
reveal a complex interplay between inflammation and brain
iron homeostasis (Righy et al., 2018; Sankar et al., 2018),
with acute inflammation increasing non-Tf iron uptake by
brain microglia (McCarthy et al., 2018). This dyshomeostasis
is especially important in acute pathologies such as stroke, in
which the impairment of the BBB regulatory role is rapidly
and massively affected following either rupture of an artery
(ICH) or aberrant increase of brain microvascular endothelial
permeability following ischemic stroke (AIS). Dysregulation of
iron resulting in the accumulation of free iron and brain iron
overload, which can increase the production of ROS, is evident
in aging and stroke-related pathologies and is also a hallmark
of chronic and long-term neurodegenerative pathologies. In
this regard, iron overload in the brain has been reported in
Huntington, Parkinson, or Alzheimer diseases [readers interested
in the topic are referred to recent detailed reviews by Morris et al.
(2018) and Uranga and Salvador (2018)]. Interestingly, marked
age-related changes in brain iron homeostasis have also been
observed in amyloid precursor protein (APP)-knockout mice
(Belaidi et al., 2018).
IRON OVERLOAD WORSENS
NEUROLOGICAL DAMAGE BOTH IN
ISCHEMIC STROKE AND
INTRACEREBRAL HEMORRHAGE
Stroke is a life-threatening disease that causes high rates of
permanent disability subsequent to neuronal loss. There are two
major types of strokes: ischemic stroke or AIS, which is caused by
a blood clot blocking an artery and accounts for 85% of all strokes,
and hemorrhagic stroke or ICH, caused by leakage or rupture of
an artery and accounts for 15% of stroke cases.
Iron Overload Condition in Stroke
Damage and Outcome
In ischemic stroke, neurons die because of interrelated processes
that include glutamate excitotoxicity, excess of free radical
production, and inflammation (Nagy and Nardai, 2017). Each
of these mechanisms has already been targeted in clinical trials,
although unsuccessfully (for a review see Chamorro et al., 2016).
Moreover, free radical-induced oxidative stress has been for long
recognized as a pathogenic factor in the ischemia/reperfusion
(I/R) injury that follows reoxygenation. The hydroxyl radical,
the most harmful of the free radicals, is generated through
reactions catalyzed by iron (Kell, 2009; Chen H. et al., 2011). Of
relevance to stroke damage and final outcome, several clinical
studies indicate that a previous systemic iron overload condition,
measured as high levels of serum FT at admission, is associated
with increased brain damage and worse outcome induced by
ischemic stroke (Davalos et al., 1994; Millan et al., 2007).
A similar detrimental effect (increased ischemic damage) was
observed in iron-overloaded animals exposed to experimental
ischemic stroke (Castellanos et al., 2002; Gamez et al., 2003;
Mehta et al., 2004; García-Yébenes et al., 2012; DeGregorio-
Rocasolano et al., 2018). Iron overload is a major source of
oxidative stress in ischemic brains (Carbonell and Rama, 2007).
In addition, iron overload exacerbated the risk of hemorrhagic
transformation in animal models of transient ischemia plus early
reperfusion (García-Yébenes et al., 2012; García-Yébenes et al.,
2018); therefore, in iron-overloaded animals, an initial ischemic
event has higher probability to become an ICH. The contribution
of iron overload to widespread the damage in the ICH is
supported by the fact that systemic iron overload (estimated using
high serum FT levels) was associated with higher perihematoma
edema and poor outcomes in patients with ICH (Mehdiratta et al.,
2008; Perez de la Ossa et al., 2010; Bakhshayesh et al., 2014;
Garton et al., 2017). Further, a combination of high serum FT
and low serum iron and Tf was associated with poor outcome
in ICH patients (Yang et al., 2016). Therefore, systemic iron
overload impacts the outcome of both ischemic and hemorrhagic
stroke patients.
The brain is physiologically sheltered from fluctuations in
systemic iron because of the BBB, even under experimentally
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induced diet iron overload conditions or intraperitoneal iron
administration (Castellanos et al., 2002; Millerot et al., 2005).
However, in the ischemic brain, the detrimental effect of iron
overload might result from systemic iron pools reaching the
brain parenchyma. Following artery occlusion, a physiological
increase in transport through a still somehow intact BBB is
noted, and thereafter pathological halt of the BBB function
that results in leaky or broken capillaries that allow blood
spill out (Figure 1). Some BBB impairment with aberrant
exchange of brain and blood molecules occurs relatively early
following ischemic stroke (within the first hours of post-symptom
onset) showing a biphasic behavior in some studies (Klohs
et al., 2009). Moreover, leakage through the BBB varies in
different experimental stroke models (Klohs et al., 2009; Abulrob
et al., 2011). Of note, post-stroke BBB leakage also varies in
different areas of the brain, whereas the administration of the
broadly used thrombolytic agent tissue plasminogen activator
increases leakage (Jaffer et al., 2013), resulting in hemorrhagic
transformation. Moreover, a recent evidence of the pivotal
contribution of BBB leakage to ischemic stroke damage has been
revealed by a study in which a vascular leakage blocker reduced
stroke damage (Zhang et al., 2017).
Effect of Stroke on Brain Iron
Regarding iron content of the brain following ischemic stroke,
an increase in total iron was observed in the ischemic areas after
permanent or transient ischemic stroke (Helal, 2008; Millerot-
Serrurot et al., 2008; Tuo et al., 2017). In addition, increased TfR
and iron levels were observed in susceptible hippocampal areas
following transient global cerebral ischemia (Park et al., 2011),
or increased extravasation of iron-loaded HTf was observed
following acute focal ischemic stroke (DeGregorio-Rocasolano
et al., 2018). In fact, HTf from blood accumulates in the brain
parenchyma of the rat ischemic brain hemisphere at 1 h after
reperfusion (DeGregorio-Rocasolano et al., 2018). Subsequently,
iron accumulates into the endothelial cells of brain capillaries
near ischemic areas (Desestret et al., 2009), whereas increased
levels of Tf were observed 24 h following a transient experimental
stroke at the ischemic hemisphere (Lo et al., 2007). In fact, this Tf
seems to accumulate in neurons since Tf immunoreactivity was
found located at the neuronal cytoplasm 24 h after stroke onset
(DeGregorio-Rocasolano et al., 2018).
In the ICH stroke type, the systemic iron pools play a direct
role in brain damage since the rupture of the microvascular wall
and concomitant blood release results in neurons, astrocytes, and
other cells around the hemorrhagic area to become immediately
exposed to blood-derived iron, either free or bound to Tf
(Figures 1, 2). Moreover, the brain is exposed to a bulk
amount of erythrocytes that undergo lysis and subsequent spill
of hemoglobin (Hb). Erythrocyte lysis occurs within minutes
and continues for days after the formation of brain hematoma,
leading to the release of red blood cell-derived products. Cells
of the brain are then sequentially exposed to aberrantly high
extracellular levels of Hb, the oxidized Hb form methemoglobin,
and free heme or the iron ferric heme form hemin. The main
mechanisms of neurodegeneration in hemorrhagic stroke are
iron- and heme-induced ROS production, amplification of an
inflammatory response, direct toxic effects of iron and heme, and
glutamate-induced excitotoxicity (Righy et al., 2016).
BRAIN REGULATION OF IRON
METABOLISM DURING STROKE
Endogenous Mechanisms Involved in the
Protection of Brain Cells From Excess
Iron Following AIS
Increased brain Tf or TfR1 levels (Ding et al., 2011; DeGregorio-
Rocasolano et al., 2018) were observed in lethal ischemia.
Consensus exists about the protective role of increased
FT expression during experimental stroke, and the same
applies to hepcidin in AIS; however, the role of blunting
the ischemia-induced upregulation of Tf and TfR remains
controversial. Reductions of Tf and TfR were considered to be
associated with neuroprotection in one specific stroke model (Lo
et al., 2007). However, other neuroprotective conditions were not
associated with Tf and/or TfR reductions (He et al., 2012).
Hepcidin seems to protect from neurodegeneration in AIS. It
is an iron-inducible peptide hormone that is considered to be
the main regulator of iron homeostasis. Hepcidin is produced
as a propeptide mainly in the liver and then secreted to the
blood where it interacts with the only known iron exporter
FPN located at the cell membrane. Hepcidin acts as a negative
regulator of cellular iron release by binding FPN and causing
its internalization and degradation; this inhibits FPN-mediated
iron egression from enterocytes, macrophages, hepatocytes and,
as recently found, some other cell types (e.g., endothelial cells
or neurons). The inhibition of iron egression, mainly from
macrophages and hepatocytes, prevents the presence of NTBI
in the blood as well as reduces the TSAT in the blood. In line
with its main function, hepcidin deficiency leads to iron overload
(Nicolas et al., 2001), and hepcidin overexpression causes severe
iron deficiency (Nicolas et al., 2002a). Hepcidin has a rapid and
direct impact on circulating iron pools. In fact, even a single
intraperitoneal administration of hepcidin reduces the TSAT in
blood to less than half the normal levels for 6−12 h (Sillerova
et al., 2012). Both blood hepcidin and HTf/apotransferrin ratio
might be considered as the master regulatory factors of systemic
iron metabolism, since hepcidin senses iron by sensing HTf
levels in the circulation and iron-FT levels inside hepatocytes.
Relevant to this review on iron and stroke, hepcidin expression
is also responsive to hypoxia (Nicolas et al., 2002b; Sonnweber
et al., 2014) mainly by the oxygen-regulated hypoxia-inducible
factor. In general, hypoxia inhibits hepcidin expression to allow
the mobilization of iron to sustain erythropoietic expansion.
However, a recent study showed that the exposure of mice to an
hypoxic environment induces biphasic modulation of hepcidin
expression with a transient increase in liver expression within the
first 6 h and a reduction after 15 h of hypoxia (Ravasi et al., 2018).
Among ischemic stroke patients, who have areas of the
brain exposed to oxygen and glucose deprivation (OGD), blood
hepcidin levels increased within the first 6 h from symptom
onset compared to those in controls; serum hepcidin levels in
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ICH patients were similar to those of controls (unpublished
results from our laboratory). This early increase in blood hepcidin
during ischemic stroke is in agreement with the early increase
reported in the hypoxic mice model (Ravasi et al., 2018)
and with the two other reports on stroke patients (Petrova
et al., 2015; Slomka et al., 2015) and might be a reflection
of an increased expression and secretion of hepcidin from
the ischemic brain cells to the extracellular medium, and a
subsequent spillover out of the brain during stroke. Although
hepcidin expression in the brain is thought to be low in basal
conditions, hepcidin is now emerging as an important player
in brain iron homeostasis (Vela, 2018). Hepcidin mRNA levels
increased early in the brain in response to ischemia in a model
of endothelin-induced vasoconstriction (Bickford et al., 2014),
and hepcidin levels were significantly elevated in the ischemic
side of the brain 24 h after occlusion in a stroke model due to
middle cerebral artery occlusion; this ischemic side also showed
increased TfR1 and FT levels and reduced FPN levels (Ding et al.,
2011). In addition, knock-down of hepcidin slows the ischemic-
mediated changes in brain FT and FPN, revealing an important
contribution of this molecule to parenchyma iron regulation
in cerebral ischemia. Further, normoxic iron-overloaded rats,
hepcidin, either overexpressed in the brain or administrated to
the brain parenchyma, reduced brain uptake of iron in vivo as
well as reduced iron uptake in cultures of neurons or brain
microvascular endothelial cells, owing to the dowregulation of
iron-transport proteins (Du et al., 2015). In microglial cells,
the bone morphogenetic protein antagonist noggin abrogated
the OGD-induced changes in hepcidin, FPN, and FT levels,
and this inhibition of bone morphogenetic protein/hepcidin
axis in vitro shifted reactive microglia from an iron-storing to
an iron-releasing phenotype after OGD plus reperfusion (Shin
et al., 2018). Factors released from noggin- and OGD-exposed
microglial culture medium were found to increase myelin
production in oligodendrocyte cell cultures; since this effect is
blunted by the iron chelator deferoxamine (DFO), iron released
from the microglia is proposed to serve in the remyelination in
the ischemic brain (Shin et al., 2018).
Endogenous Mechanisms Involved in the
Protection of Brain Cells From Excess
Iron Following ICH
Similar to that observed in AIS, subarachnoid hemorrhage has
been shown to increase hepcidin expression in neurons (Zhao
et al., 2018) associated with a reduction of its downstream
target FPN (Tan et al., 2016). However, in this hemorrhage
model, hepcidin seems to be harmful since its administration
potentiated and its siRNA decreased apoptosis and early brain
damage (Tan et al., 2016). In agreement with a harmful
effect of hepcidin on brain hemorrhage, higher blood hepcidin
levels were observed 1−7 days following ICH in patients
with poorer outcomes (Xiong et al., 2015). The rationale
for this harmful effect of hepcidin following ICH might be
an impaired clearance of iron from brain parenchyma, since
increased hepcidin expression caused by inflammation was found
to inhibit intracellular iron efflux from brain microvascular
endothelial cells and further draining of iron into circulation,
leading to the aggravation of oxidative brain injury (Xiong
et al., 2016). Conversely, addition of hepcidin or adenovirus-
driven overexpression of hepcidin has been shown to protect
neurons from hemin-induced injury (Zhou et al., 2017); this
protection was thought to be related to the effect of hepcidin
reducing hemin-induced iron uptake and reduced expression of
TfR1 and DMT1.
Moreover, importantly, stroke has an inflammatory
component, and some inflammatory inducers or mediators
(e.g., lipopolysaccharide or interleukin 6) have been found to
increase the expression of hepcidin in astrocytes, microglia, or
neurons (for a recent review see Vela, 2018), although the effect
on neurons is usually weaker (Ma et al., 2018).
The brain has protective mechanisms that can be activated
after ICH and erythrocyte lysis, the most important one being
the Hb-scavenging molecule haptoglobin (Hp) and the heme-
scavenging system hemopexin (Hpx) (Figure 2). Hb itself is
avidly bound by Hp to form a complex that prevents the release
of the heme group from Hb or methemoglobin. However, Hp
cannot prevent the release of the heme group from the highest
oxidative Hb form ferrylHb. In the brain, Hp is almost exclusively
synthesized by oligodendrocytes, and mice overexpressing Hp
were more resistant, whereas Hp-knockout mice were more
susceptible, to ICH injury (Zhao et al., 2011). The complex
Hp:Hb binds to the Hp-specific receptor CD163 that is present in
macrophages, allowing them to remove Hb from the extracellular
space. In addition, CD163 is upregulated in neurons after ICH
(Liu et al., 2017). The role of Hp in neuroprotection was not
devoid of controversy since Hp was found to exacerbate the
vulnerability of CD163-expressing neurons to Hb, an effect that
was reduced by iron chelators (Chen-Roetling and Regan, 2016).
However, most Hb was not bound to Hp, indicating that the
CD163–Hb–Hp system is saturated, and that the primary route
for Hb clearance from the CNS occurs through the BBB (Galea
et al., 2012; Righy et al., 2018). A good clearance is associated
with neuroprotection since lower CSF Hp levels were found in
ICH patients without clinical and/or radiological evidence of
delayed cerebral ischemia (Galea et al., 2012). Hb accumulated
in the brain parenchyma is converted to ferrylHb, which
causes the upregulation of proinflammatory adhesion molecules
and increases the recruitment of inflammatory neutrophils or
macrophages (Jeney et al., 2013).
Iron–hemin uptake has been reported in neurons and
astrocytes and is especially high in microglial cell cultures;
neurons benefit from a high export of iron following the
initial iron–hemin loading, and this export was exacerbated
by treatment with DFO, a compound that attenuates hemin
neurotoxicity (Chen-Roetling et al., 2014). As already mentioned,
the brain produces the heme scavenger protein Hpx that
protects from deleterious effects of heme. In this regard,
deletion/knockout of the Hpx aggravates brain injury by ICH
(Chen L. et al., 2011; Ma et al., 2016) and, although endogenous
levels of Hpx are insufficient to counteract the massive heme
overload following ICH, increasing brain Hpx levels has been
found to improve the outcome after ICH (Leclerc et al., 2018).
Conversely, Hpx has recently been reported to increase the
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neurotoxicity of Hb in the absence of Hp (Chen-Roetling et al.,
2018). Therefore, although both Hp and Hpx might provide a
robust line of defense during ICH, additional knowledge on the
fine tuning of this system is still required to design new possible
neuroprotective treatments for ICH. The low-density lipoprotein
receptor-related protein CD91 is expressed in several cell
types, including macrophages and neurons, and was identified
as the Hpx–heme receptor, mediating Hpx–heme uptake by
endocytosis (Hvidberg et al., 2005). Once inside the cell, the
heme oxygenase (HO) system is responsible for cellular heme
degradation. In neurons, HO generates biliverdin, which has been
reported to scavenge free radicals. Astrocytes rapidly upregulate
HO1 and FT and are resistant to heme-mediated injury, and
astrocyte HO1 is known to play a robust neuroprotective role
after hemorrhage (Chen-Roetling et al., 2017). A recent study
indicated that Hpx activates endothelial progenitor cells and
reduces synaptic damage in a rodent ischemic stroke model; these
effects require HO1 activity (Yang et al., 2018).
Moreover, the presence of heme groups in the extracellular
milieu activates the endothelial expression of adhesion molecules
and promotes the activation of neutrophil extracellular traps
through a mechanism dependent on ROS generation (Chen et al.,
2014). Further, inflammatory response is a well-documented
mechanism of brain damage after ICH (Wang and Doré, 2007),
and the mechanisms underlying heme-induced inflammation
have been reviewed elsewhere (Dutra and Bozza, 2014). Iron
and heme associated with pro-inflammatory mediators in the
CNS following hemorrhagic stroke and inflammatory profiles
are associated with poorer prognosis. Similarly, iron-induced
damage following ischemic stroke in iron-overloaded animals has
also been related to increased inflammatory responses associated
with increased serum levels of interleukin 6 and TNF-alpha
(Castellanos et al., 2002).
THE FERROPTOTIC COMPONENT OF
STROKE-INDUCED
NEURODEGENERATION
The Concept of Ferroptosis: Molecular
Players Involved in Ferroptosis in the
Neurons
The concept of ferroptosis was introduced as a form of cell
death, which is morphologically, biochemically, and genetically
distinct from apoptosis, necrosis, and autophagy; it is associated
with excessive iron-mediated accumulation of lipid ROS in
cancer cells as well as in hippocampal slice cultures exposed to
glutamate excitotoxicity (Dixon et al., 2012). As excitotoxicity
is the main mechanism involved in neuronal death in ischemic
stroke, the involvement of ferroptosis in ischemic stroke could be
suspected. In addition, the role of high systemic iron exacerbating
stroke-induced damage, concomitant with increased brain iron
after ischemic stroke onset (reviewed in the previous section),
further suggested a possible ferroptosis component in stroke;
in the recent past, mounting evidence indicated that ferroptosis
plays such a pivotal role in stroke-induced neurodegeneration
in both ischemic and hemorrhagic stroke subtypes. Although
the concept is still evolving, ferroptosis is now considered a
unique form of regulated cell death characterized by cytosolic
accumulation of iron and executed by the massive peroxidation
of PUFA in the plasma membrane and associated with
reduced glutathione (GSH). Compounds that induce only either
cytosolic or mitochondrial ROS production are not considered
as ferroptosis inducers. A recent study proposed that both
Fenton reactions, in which Fe2+ converts to Fe3+ producing
ROS, and enzymatic lipoxygenase-mediated reactions in cellular
membranes contribute to ferroptosis (Feng and Stockwell, 2018).
Some authors considered that the ferroptosis concept and the
previously described oxidative oxytosis concept have many
common features to be regarded as independent processes
(Lewerenz et al., 2018). In fact, the widely used oxidative
stress stimulus tert-butylhydroperoxide was found to induce
neuronal cell death that was blocked by ferroptosis inhibitors,
thereby implying a crosstalk between the initial oxidative damage
and the occurrence of ferroptosis (Wu et al., 2018). However,
ferroptosis is considered a major driver of cell death in many
neurodegenerative and neurological diseases (Lewerenz et al.,
2018; Morris et al., 2018).
Ferroptosis can be triggered by the inhibitors of the lipid
repair enzyme glutathione peroxidase 4 (GPX4), such as the
RAS-selective lethal 3 compound, or depletion of the antioxidant
GSH by starving the cells of GSH precursors [inhibiting
the cystine/glutamate antiporter, i.e., system X−c (X
−
c ) with
erastin, sulfasalazine, sorafenib, or, alternatively, challenging the
exchange capacity of X−c with high extracellular glutamate].
Extracellular Tf in its iron-loaded HTf form is considered as
an inducer of ferroptosis as well, and inhibiting TfR expression
prevents ferroptosis (Gao et al., 2015).
At present, the existence of X−c in neurons is still controversial,
with one report showing expression lack of X−c in neurons
(Ottestad-Hansen et al., 2018), whereas another showing neurons
expressing significant X−c levels (Soria et al., 2016). However,
neurons in culture overexpress X−c shortly after being exposed
to OGD (Soria et al., 2014). The physiological role of X−c as a
cystine importer is linked to its antiporter glutamate export and
requires that extracellular levels of glutamate and other excitatory
amino acids are maintained low by the action of excitatory
amino acid transporters (EAATs). Thus, one of these glutamate
transporters, the sodium-dependent EAAT3, might be selectively
expressed in neurons and could also be an unidirectional
cysteine import channel, with extracellular glutamate inhibiting
its cysteine import capacity (Watts et al., 2014). EAAT3 might
be as important as X−c in providing GSH precursors to neurons,
considering that mice lacking EAAT3 have lower GSH levels
and age prematurely (Aoyama et al., 2006). Notably, low GSH
levels might also inhibit GPX4 activity since GPX4 uses GSH as
a cofactor to catalyze the reduction of lipid peroxides and protect
cells membranes against peroxidation (see Latunde-Dada, 2017).
Conversely, ferroptosis can be prevented by (1) iron-
binding compounds such as DFO and ciclopirox; (2) small
molecules, free radical scavengers, or lipophilic antioxidants
such as ferrostatin-1, α-tocopherol, butylated hydroxytoluene, or
liproxstatin-1; (3) treatments with molecules such as deuterated
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PUFA, inhibitors of acyl-CoA synthetase long-chain family
member 4, lipoxygenase inhibitors, glutaminolysis inhibitors, or
cycloheximide; or (4) boosting cystine and/or cysteine import by
reducing extracellular glutamate.
Glutamate is the most abundant excitatory neurotransmitters
in the vertebrate nervous system, with 90% of the synaptic
neurotransmission considered glutamatergic (Hofmeijer and Van
Putten, 2012; Mayor and Tymianski, 2018). Under physiological
conditions, extracellular glutamate levels are low, and glutamate
exerts its physiological role mainly at the neuronal synapse.
The ability of astrocytes near glutamatergic neurons to rapidly
clear synaptic glutamate after its physiological action is critical
in the functioning of synapses and neuronal circuits, and the
initial increase of extracellular glutamate is inhibited mainly
by glial EAAT1 and 2. Neuronal glutamate transporters,
mainly EAAT3, also play a role in clearing extracellular
glutamate excess. However, ischemia leads to energy failure
and subsequent electrochemical gradient impairment, causing
EAATs to act in a reversed manner, thereby extruding non-
vesicular intracellular glutamate and resulting in large excess
of extracellular glutamate and impairment of EAAT3 as a
unidirectional cysteine import channel.
The impact of excess extracellular glutamate on neuronal
survival is more than that on the cystine/glutamate exchanger X−c .
In fact, most of the effect is produced by glutamate binding to
specific glutamate receptors present in cell membranes of several
cell types and, especially in neurons, N-methyl-D-aspartate
(NMDA) subtype of glutamate receptors (NMDARs) (Guirao
et al., 2017) that are coupled to an intracellular downstream
complex of signaling effectors, which are known to initiate
excitotoxic neuronal death following ischemia.
Although both glutamate and iron are essential for neuronal
survival, excess glutamate can be toxic, and excess free iron
through the Fenton reaction is a potentially toxic substance
that can catalyze the production of extremely damaging
ROS. During stroke, the impairment of BBB function allows
increased access to brain of iron-carrying substances and,
preceding neurodegeneration, iron accumulates in the ischemic
areas (Helal, 2008); therefore, not surprisingly, iron overload
conditions are associated with larger areas of brain damage in
animals exposed to experimental ischemic stroke (Castellanos
et al., 2002; Gamez et al., 2003; Mehta et al., 2004; García-
Yébenes et al., 2012; DeGregorio-Rocasolano et al., 2018).
Following experimental stroke or NMDAR overactivation,
prevention of NMDA-induced neuronal iron uptake was found
to be neuroprotective (DeGregorio-Rocasolano et al., 2018).
Therefore, the crosstalk between neuronal homeostasis of iron
and glutamatergic signaling is increasingly being supported
by evidence and should not be disregarded as a therapeutic
intervention target.
Glutamate-Induced Iron Uptake in
Neurons and Ferroptosis
Cheah et al. (2006) from Dr. Snyder’s laboratory published a
study before the concept of ferroptosis was introduced and
showed that the overactivation of NMDAR in neurons induces,
in addition to the well-known NMDAR-mediated calcium
influx, an NMDAR-mediated iron uptake. They also identified
a signaling cascade whereby NMDAR regulated neuronal
iron homeostasis and excitotoxicity through an NMDAR/nitric
oxide/dexamethasone-induced Ras protein 1 (Dexras1) pathway
that increased both non-Tf and Tf-mediated iron uptake from the
extracellular medium through the neuronal plasma membrane
(Cheah et al., 2006). A similar increase of iron uptake in
hippocampal neurons was observed in a subsequent study in
which either synaptic activity or NMDAR activity was boosted
(Pelizzoni et al., 2011). Moreover, either ischemia or NMDA
overactivation increased the uptake of HTf, resulting in an
increase of cytosolic redox-active iron in neurons, whereas
blockade of TfR1 reduced iron dyshomeostasis and NMDA-
induced excitotoxicity (DeGregorio-Rocasolano et al., 2018).
The original work from Snyder’s laboratory hypothesized that
iron in its free form gains access to the neuronal cytosol
through DMT1 present in the neuronal membrane. However,
this would not explain the uptake of Tf-bound iron since the
DMT1 isoform endogenously overexpressed in primary cultures
of hippocampal neurons exposed to NMDA is DMT1-1B/IRE(+)
(Haeger et al., 2010) and is found in endosomes/lysosomes in
the cytoplasm (Pelizzoni et al., 2012), thereby not supporting
a direct role of DMT1 in iron entry through the neuronal
membrane. Following the above rationale of crossroads between
excitotoxicity and ferroptosis, several in vitro and in vivo
studies showed that neurons survive otherwise lethal NMDA
or glutamate concentrations when treated with iron chelators
such as DFO or deferasirox (Yu et al., 2009; Tian et al.,
2017; Sakamoto et al., 2018). Moreover, a study showed that
the deletion of Dexras1 reduced NMDA-induced iron uptake
and NMDA toxicity in cortical neurons and retinal ganglion
cells (Chen et al., 2013). Moreover, Dexras1-KO mice showed
increased expression of the NR2A subunit of the NMDAR
(Carlson et al., 2016), a subunit that is preferentially located
at synapses and related to NMDAR pro-survival signaling;
this strongly suggests the existence of a functional crosstalk
between the NMDA-induced iron intracellular signaling and the
physiological NMDAR function. Interestingly, intracellular iron
released from lysosomes has been shown to modulate NMDAR
synaptic excitability via Dexras1 (White et al., 2016), and iron is
needed post-synaptically to activate Ca2+-dependent pathways
downstream NMDAR (Muñoz et al., 2011). Further, glutamate-
induced neuronal excitotoxicity was described as ferroptosis
(Dixon et al., 2012).
In the widely reported scenario of elevated extracellular
glutamate during ischemic stroke, NMDAR-induced iron import
was upregulated in neurons associated with increased ROS
production (Cheah et al., 2006), and system X−c and EAAT3
cystine/cysteine import are impaired by high extracellular
glutamate (Conrad and Sato, 2012), thus compromising neuronal
iron homeostasis and GSH-mediated free radical detoxification,
eventually leading to an excess lipid oxidative stress that
causes ferroptotic damage. High GSH stores are pivotal for
cell survival since GSH is required for GPX4 activity and
is also thought to be the only molecular species having a
significant role as a cytosolic ligand for Fe2+ (Philpott and
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Ryu, 2014). Even when ischemia is resolved in the brain owing
to a successful reperfusion, other mechanisms involved in
ferroptotic damage might become dangerous. In this regard, a
recent study on Sertoli cells revealed that GPX4 is inactivated
via GSH depletion following I/R injury (Li et al., 2018), and
several studies showed that GPX4 gene inactivation causes
hippocampal neurodegeneration (Seiler et al., 2008; Hambright
et al., 2017) and a remarkable degeneration of motor neurons
(Chen et al., 2015).
Ferroptosis in AIS and ICH Stroke
Subtypes: Effect of Ferroptosis Inhibitors
and Iron Chelators
In addition to a pivotal role of ferroptosis in I/R-induced damage
in several peripheral organs (Friedmann Angeli et al., 2014;
Linkermann et al., 2014; Gao et al., 2015), a role of ferroptosis
has been specifically identified in I/R-induced brain damage in
transient ischemia, as brain damage was substantially reduced
by the ferroptosis inhibitor liproxstatin-1 in an AIS model (Tuo
et al., 2017). These authors also showed that a reduction of
tau levels, a protein that facilitates iron export by trafficking
APP to membranes to stabilize FPN, was found to precede a
pro-ferroptotic iron accumulation in the brain following I/R
(Tuo et al., 2017). APP mRNA possesses a functional IRE
with sequence homology to that of FT, and its translation is
responsive to free iron levels in the cytosol (Duce et al., 2010).
In addition, APP has been reported to interact with FPN to
promote iron release in several brain cell types (Duce et al.,
2010; McCarthy et al., 2014). APP overexpression reduces free
iron content in neuroblastoma cells (Wan et al., 2012), and
either preventing APP transport to the cell surface or knocking
down of APP results in iron accumulation in primary cortical
neurons in culture (Lei et al., 2012). The complete role of APP
in ferroptosis and neurodegeneration in AIS requires additional
studies. However, further evidence supporting the involvement
of ferroptosis mechanisms in AIS brain damage is provided by
the overexpression of lipoxygenases following brain ischemia and
the protection afforded by treatment with lipoxygenase inhibitors
(Cui et al., 2010; Karatas et al., 2018). Further, a recent study
showed that N-acetylcysteine (NAC), an FDA-approved cysteine
prodrug, prevents hemin-induced ferroptosis by neutralizing
toxic lipids generated by arachidonate-dependent activity of 5-
lipoxygenases (ALOX5) (Karuppagounder et al., 2018). They
reported that ALOX5 inhibitors such as zileuton and molecules
such as NAC that inhibit toxic metabolic products of ALOX5
or prevent ALOX5 recruitment to its site of action, protect
against hemin or ICH-induced ferroptosis (Karuppagounder
et al., 2018). Notably, NAC has been previously reported to
prevent neuronal damage induced by AIS (Khan et al., 2004;
Turkmen et al., 2016).
Further, the role of free iron in ferroptosis and
neurodegeneration is further supported by the protective
effect of treatments with exogenous iron chelators, e.g., DFO
or 2,2′-dipyridyl, in animal models of stroke. After permanent
ischemic stroke (Millerot-Serrurot et al., 2008), the increase
in free iron, the iron form prone to induce lipid peroxidation
and susceptible to be chelated, precedes the increase in total
iron. In experimental models of transient ischemic stroke,
DFO administered intramuscularly (Xing et al., 2009) or
intranasally (Hanson et al., 2009) after the induction of
ischemia significantly decreased infarct volume. Another iron
chelator, the aforementioned 2,2’-dipyridyl was found to be
cytoprotective after permanent arterial occlusion in rats; this was
associated with reduced infarct size and preservation of GSH
levels (Demougeot et al., 2004) or reduction of the apoptotic
component and prevention of the enlargement of the lesion
(Van Hoecke et al., 2005).
The role of iron in ICH neurodegeneration has been known
for long. Recently, neuronal death following ICH was found
to have features similar to those of ferroptosis, since chemical
inhibitors of ferroptosis protected against Hb- and hemin-
induced neurotoxicity (Zille et al., 2017). The nonheme iron
present in brain parenchyma after ICH is a source of redox-
active iron. The marked increase in brain nonheme iron was
not cleared for weeks following the ICH event, and brain
Tf, TfR, and FT levels were also increased 72 h after ICH,
thereby making FT upregulation long-lasting (Wu et al., 2003).
Iron chelators such as DFO reduce hemin- and iron-mediated
neurotoxicity, perihematoma edema, and neuronal damage,
leading to good neurologic outcomes after ICH (Nakamura
et al., 2004; Hatakeyama et al., 2013). Other recent studies
indicated that the specific inhibitor of ferroptosis ferrostatin-1
reduces neuron degeneration and improves neurological deficit
in experimental ICH models (Li Q. et al., 2017; Zhang et al., 2018),
and GPX4 levels were found to be reduced after ICH, whereas
pharmacological inhibition of GPX or genetic knockdown
exacerbated brain injury after ICH (Zhang et al., 2018). Moreover,
inhibitors of ALOX5 or inhibition of the ALOX5 metabolic
products protected against hemin- or ICH-induced ferroptosis
(Karuppagounder et al., 2018).
Moreover, DFO significantly reduced hemorrhagic
transformation after focal I/R (Xing et al., 2009; Li Y. et al.,
2017). Some studies have shown that the effect of DFO in
preventing ischemic neuronal death is related to the DFO-
induced expression of hypoxia-inducible factor 1 and its
downstream targets genes rather than with its iron-chelating
properties or, recently, with microglial/macrophage HO1
expression in ICH (LeBlanc et al., 2016). A systematic review
and meta-analysis in experimental models of ICH showed that
DFO was neuroprotective, e.g., reduction of brain edema and
improvement of neurobehavioral outcomes, especially when
it was administered 2−4 h after ICH induction (Cui et al.,
2015). In clinical studies, conclusive evidence of the benefit of
DFO treatment in ICH (Zeng et al., 2018) or AIS patients is
still lacking; some clinical trials of DFO in ICH and AIS are
currently ongoing.
The rationale for iron chelation as a neuroprotectant relies
primarily on the idea that chelation removes free iron present
in the blood and enhances iron elimination in the urine. After
gaining access to other body compartments, DFO could also
act by chelating free extracellular and cytosolic iron, whereas
its effect on blood TSAT or blood total iron levels is modest
(Tauchenová et al., 2016). In fact, DFO was shown to have
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an extremely slow removal rate of iron from Tf (Abergel
and Raymond, 2008). This, together with the fact that DFO
half-life in the plasma is extremely short (20 min), poses
serious doubts about the effectiveness of the treatment with
intravenous DFO unless administered with continuous infusion.
Recently, another iron-regulator, apotransferrin, administered
after stroke AIS onset, was found to be neuroprotective because
of the systemic reduction of blood TSAT and a reduction of
NMDA ischemia-induced neuronal iron import (DeGregorio-
Rocasolano et al., 2018).
CONCLUSION
Increasing number of studies show that ferroptosis is involved
in several neurodegenerative diseases. This review summarizes
the knowledge available thus far regarding the role of iron and
ferroptosis in the execution of neuronal cell death during AIS
and ICH. In AIS-induced cell death, the role of systemic iron,
Tf, TSAT, and hepcidin on excitotoxic damage, infarct size, and
neurological outcome in rodent models of stroke might have
important clinical implications. Following the AIS event, high
levels of extracellular glutamate and impairment of the BBB
allow the NMDAR-mediated influx of iron, either bound or not
to Tf, into neurons. In addition, high extracellular glutamate
prevents the neuronal production of the antioxidant GSH or the
function of GPX4, thereby promoting a form of cell death in
which glutamate receptor overactivation boosts neuronal iron
uptake, which in turn promotes an overwhelming production of
membrane peroxides. The role of iron in ICH neurodegeneration
has been known for long, since blood spillover results
in iron-Hb and iron–heme complexes at the extracellular
milieu of brain parenchymal cells, thereby contributing to
iron-induced lipid peroxidation and neuronal death. The
review documents the beneficial effects of iron chelators
such as DFO, physiological molecules with neuroprotective
potential, and specific inhibitors of ferroptosis liproxstatin-1 or
ferrostatin-1 in reducing neuron degeneration and improving
neurologic deficits induced by ischemic and hemorrhagic
stroke subtypes.
AUTHOR CONTRIBUTIONS
The three authors have contributed in a similar way to the writing
of the article.
FUNDING
This study was supported by the following grants: Instituto
de Salud Carlos III (ISCIII) INVICTUS PLUS RD16/0019/0020
that was susceptible to be co-financed by FEDER funds and
Agència de Gestió d’Ajuts Universitaris i de Recerca 2017 SGR
1520. We acknowledge the funding received from “la Caixa”
Foundation CI15-00009 and from the European Institute of
Innovation and Technology (EIT) PoC-2016-SPAIN-04. EIT
receives support from the European Union’s Horizon 2020
research and innovation program.
REFERENCES
Abergel, R. J., and Raymond, K. N. (2008). Terephthalamide-containing ligands:
fast removal of iron from transferrin. J. Biol. Inorg. Chem. 13, 229–240. doi:
10.1007/s00775-007-0314-y
Abulrob, A., Brunette, E., Slinn, J., Baumann, E., and Stanimirovic, D. (2011).
In vivo optical imaging of ischemic blood-brain barrier disruption. Methods
Mol. Biol. 763, 423–429. doi: 10.1007/978-1-61779-191-8_29
Acikyol, B., Graham, R. M., Trinder, D., House, M. J., Olynyk, J. K., Scott, R. J.,
et al. (2013). Brain transcriptome perturbations in the transferrin receptor 2
mutant mouse support the case for brain changes in iron loading disorders,
including effects relating to long-term depression and long-term potentiation.
Neuroscience 235, 119–128. doi: 10.1016/j.neuroscience.2013.01.014
Aoyama, K., Sang, W. S., Hamby, A. M., Liu, J., Wai, Y. C., Chen, Y., et al. (2006).
Neuronal glutathione deficiency and age-dependent neurodegeneration in the
EAAC1 deficient mouse. Nat. Neurosci. 9, 119–126. doi: 10.1038/nn1609
Arosio, P., Elia, L., and Poli, M. (2017). Ferritin, cellular iron storage and
regulation. IUBMB Life 69, 414–422. doi: 10.1002/iub.1621
Asano, T., Komatsu, M., Yamaguchi-Iwai, Y., Ishikawa, F., Mizushima, N., and
Iwai, K. (2011). Distinct mechanisms of ferritin delivery to lysosomes in iron-
depleted and iron-replete cells. Mol. Cell. Biol. 31, 2040–2052. doi: 10.1128/
MCB.01437-10
Ashraf, A., Clark, M., and So, P. W. (2018). The aging of iron man. Front. Aging
Neurosci. 10:65. doi: 10.3389/fnagi.2018.00065
Bakhshayesh, B., Hosseininezhad, M., Saadat, S., Ansar, M., Ramezani, H.,
and Saadat, S. (2014). Iron overload is associated with perihematoma
edema growth following intracerebral hemorrhage that may contribute
to in-hospital mortality and long-term functional outcome. Curr.
Neurovasc. Res. 11, 248–253. doi: 10.2174/15672026116661405301
24855
Belaidi, A. A., Gunn, A. P., Wong, B. X., Ayton, S., Appukuttan, A. T., Roberts,
B. R., et al. (2018). Marked age-related changes in brain iron homeostasis in
amyloid protein precursor knockout mice. Neurotherapeutics 15, 1055–1062.
doi: 10.1007/s13311-018-0656-x
Bickford, J. S., Ali, N. F., Nick, J. A., Al-Yahia, M., Beachy, D. E., Doré, S., et al.
(2014). Endothelin-1-mediated vasoconstriction alters cerebral gene expression
in iron homeostasis and eicosanoid metabolism. Brain Res. 1588, 25–36. doi:
10.1016/j.brainres.2014.09.022
Bradbury, M. W. (1997). Transport of iron in the blood-brain-cerebrospinal fluid
system. J. Neurochem. 69, 443–454. doi: 10.1046/j.1471-4159.1997.69020443.x
Burdo, J. R., Menzies, S. L., Simpson, I. A., Garrick, L. M., Garrick, M. D.,
Dolan, K. G., et al. (2001). Distribution of divalent metal transporter 1 and
metal transport protein 1 in the normal and Belgrade rat. J. Neurosci. Res. 66,
1198–1207. doi: 10.1002/jnr.1256
Carbonell, T., and Rama, M. (2007). Iron, oxidative stress and early neurological
deterioration in ischemic stroke. Curr. Med. Chem. 14, 857–874. doi: 10.2174/
092986707780363014
Carlson, G. C., Lin, R. E., Chen, Y., Brookshire, B. R., White, R. S., Lucki, I.,
et al. (2016). Dexras1 a unique ras-GTPase interacts with NMDA receptor
activity and provides a novel dissociation between anxiety, working memory
and sensory gating. Neuroscience 322, 408–415. doi: 10.1016/j.neuroscience.
2016.02.063
Castellanos, M., Puig, N., Carbonell, T., Castillo, J., Martinez, J. M., Rama, R., et al.
(2002). Iron intake increases infarct volume after permanent middle cerebral
artery occlusion in rats. Brain Res. 952, 1–6. doi: 10.1016/S0006-8993(02)
03179-7
Chamorro, Á, Dirnagl, U., Urra, X., and Planas, A. M. (2016). Neuroprotection
in acute stroke: targeting excitotoxicity, oxidative and nitrosative stress,
and inflammation. Lancet Neurol. 15, 869–881. doi: 10.1016/S1474-4422(16)
00114-9
Frontiers in Neuroscience | www.frontiersin.org 12 February 2019 | Volume 13 | Article 85
fnins-13-00085 February 15, 2019 Time: 19:40 # 13
DeGregorio-Rocasolano et al. The Iron Side of Stroke
Cheah, J. H., Kim, S. F., Hester, L. D., Clancy, K. W., Patterson, S. E.,
Papadopoulos, V., et al. (2006). NMDA receptor-nitric oxide transmission
mediates neuronal iron homeostasis via the GTPase Dexras1. Neuron 51,
431–440. doi: 10.1016/j.neuron.2006.07.011
Chen, G., Zhang, D., Fuchs, T. A., Manwani, D., Wagner, D. D., and Frenette,
P. S. (2014). Heme-induced neutrophil extracellular traps contribute to the
pathogenesis of sickle cell disease. Blood 123, 3818–3827. doi: 10.1182/blood-
2013-10-529982
Chen, H., Yoshioka, H., Kim, G. S., Jung, J. E., Okami, N., Sakata, H., et al.
(2011). Oxidative stress in ischemic brain damage: mechanisms of cell death
and potential molecular targets for neuroprotection. Antioxid. Redox Signal. 14,
1505–1517. doi: 10.1089/ars.2010.3576
Chen, L., Zhang, X., Chen-Roetling, J., and Regan, R. F. (2011). Increased striatal
injury and behavioral deficits after intracerebral hemorrhage in hemopexin
knockout mice. J. Neurosurg. 114, 1159–1167. doi: 10.3171/2010.10.JNS10861
Chen, L., Hambright, W. S., Na, R., and Ran, Q. (2015). Ablation of the ferroptosis
inhibitor glutathione peroxidase 4 in neurons results in rapid motor neuron
degeneration and paralysis. J. Biol. Chem. 290, 28097–28106. doi: 10.1074/jbc.
M115.680090
Chen, Y., Khan, R. S., Cwanger, A., Song, Y., Steenstra, C., Bang, S.,
et al. (2013). Dexras1, a small GTPase, is required for glutamate-NMDA
neurotoxicity. J. Neurosci. 33, 3582–3587. doi: 10.1523/JNEUROSCI.1497-12.
2013
Chen-Roetling, J., Cai, Y., Lu, X., and Regan, R. F. (2014). Hemin uptake and release
by neurons and glia. Free Radic. Biol. Med. 48, 200–205. doi: 10.3109/10715762.
2013.859386
Chen-Roetling, J., Kamalapathy, P., Cao, Y., Song, W., Schipper, H. M., and Regan,
R. F. (2017). Astrocyte heme oxygenase-1 reduces mortality and improves
outcome after collagenase-induced intracerebral hemorrhage. Neurobiol. Dis.
102, 140–146. doi: 10.1016/j.nbd.2017.03.008
Chen-Roetling, J., Ma, S.-K., Cao, Y., Shah, A., and Regan, R. F. (2018).
Hemopexin increases the neurotoxicity of hemoglobin when haptoglobin is
absent. J. Neurochem. 145, 464–473. doi: 10.1111/jnc.14328
Chen-Roetling, J., and Regan, R. (2016). Haptoglobin increases the vulnerability
of CD163-expressing neurons to hemoglobin. J. Neurochem. 139, 586–589.
doi: 10.1111/jnc.13720
Chiou, B., Lucassen, E., Sather, M., Kallianpur, A., and Connor, J. (2018a).
Semaphorin4A and H-ferritin utilize Tim-1 on human oligodendrocytes: a
novel neuro-immune axis. Glia 66, 1317–1330. doi: 10.1002/glia.23313
Chiou, B., Neal, E. H., Bowman, A. B., Lippmann, E. S., Simpson, I. A., and
Connor, J. R. (2018b). Endothelial cells are critical regulators of iron transport
in a model of the human blood–brain barrier. J. Cereb. Blood Flow Metab.
doi: 10.1177/0271678X18783372 [Epub ahead of print].
Cobley, J. N., Fiorello, M. L., and Bailey, D. M. (2018). 13 Reasons why the brain
is susceptible to oxidative stress. Redox Biol. 15, 490–503. doi: 10.1016/j.redox.
2018.01.008
Conrad, M., and Sato, H. (2012). The oxidative stress-inducible cystine/glutamate
antiporter, system Xc-: cystine supplier and beyond. Amino Acids 42, 231–246.
doi: 10.1007/s00726-011-0867-5
Cui, H. J., He, H. Y., Yang, A. L., Zhou, H. J., Wang, C., Luo, J. K., et al. (2015).
Efficacy of deferoxamine in animal models of intracerebral hemorrhage: a
systematic review and stratified meta-analysis. PLoS One 10:e0127256. doi:
10.1371/journal.pone.0127256
Cui, L., Zhang, X., Yang, R., Liu, L., Wang, L., Li, M., et al. (2010). Baicalein
is neuroprotective in rat MCAO model: role of 12/15-lipoxygenase, mitogen-
activated protein kinase and cytosolic phospholipase A2. Pharmacol. Biochem.
Behav. 96, 469–475. doi: 10.1016/j.pbb.2010.07.007
Das, A., Nag, S., Mason, A. B., and Barroso, M. M. (2016).
Endosome–mitochondria interactions are modulated by iron release
from transferrin. J. Cell Biol. 214, 831–845. doi: 10.1083/jcb.201
602069
Davalos, A., Fernandez-Real, J. M., Ricart, W., Soler, S., Molins, A., Planas, E., et al.
(1994). Iron-related damage in acute ischemic stroke. Stroke 25, 1543–1546.
doi: 10.1161/01.STR.25.8.1543
De Valk, B., Addicks, M. A., Gosriwatana, I., Lu, S., Hider, R. C., and Marx,
J. J. M. (2000). Non-transferrin-bound iron is present in serum of hereditary
haemochromatosis heterozygotes. Eur. J. Clin. Invest. 30, 248–251. doi: 10.1046/
j.1365-2362.2000.00628.x
Deane, R., Zheng, W., and Zlokovic, B. V. (2004). Brain capillary endothelium and
choroid plexus epithelium regulate transport of transferrin-bound and free iron
into the rat brain. J. Neurochem. 88, 813–820. doi: 10.1046/j.1471-4159.2003.
02221.x
DeGregorio-Rocasolano, N., Martí-Sistac, O., Ponce, J., Castelló-Ruiz, M.,
Millán, M., Guirao, V., et al. (2018). Iron-loaded transferrin (Tf) is detrimental
whereas iron-free Tf confers protection against brain ischemia by modifying
blood Tf saturation and subsequent neuronal damage. Redox Biol. 15, 143–158.
doi: 10.1016/j.redox.2017.11.026
Demougeot, C., Van Hoecke, M., Bertrand, N., Prigent-Tessier, A., Mossiat, C.,
Beley, A., et al. (2004). Cytoprotective efficacy and mechanisms of the
liposoluble iron chelator 2,2’-dipyridyl in the rat photothrombotic ischemic
stroke model. J. Pharmacol. Exp. Ther. 311, 1080–1087. doi: 10.1124/jpet.104.
072744
Desestret, V., Brisset, J. C., Moucharrafie, S., Devillard, E., Nataf, S., Honnorat, J.,
et al. (2009). Early-stage investigations of ultrasmall superparamagnetic iron
oxide-induced signal change after permanent middle cerebral artery occlusion
in mice. Stroke 40, 1834–1841. doi: 10.1161/STROKEAHA.108.531269
Ding, H., Yan, C. Z., Shi, H., Zhao, Y. S., Chang, S. Y., Yu, P., et al. (2011). Hepcidin
is involved in iron regulation in the ischemic brain. PLoS One 6:e25324. doi:
10.1371/journal.pone.0025324
Dixon, S. J., Lemberg, K. M., Lamprecht, M. R., Skouta, R., Zaitsev, E. M., Gleason,
C. E., et al. (2012). Ferroptosis: an iron-dependent form of nonapoptotic cell
death. Cell 149, 1060–1072. doi: 10.1016/j.cell.2012.03.042
Drecourt, A., Babdor, J., Dussiot, M., Petit, F., Goudin, N., Garfa-Traoré, M.,
et al. (2018). Impaired transferrin receptor palmitoylation and recycling in
neurodegeneration with brain iron accumulation. Am. J. Hum. Genet. 102,
266–277. doi: 10.1016/j.ajhg.2018.01.003
Du, F., Qian, Z. M., Luo, Q., Yung, W. H., and Ke, Y. (2015). Hepcidin suppresses
brain iron accumulation by downregulating iron transport proteins in iron-
overloaded rats. Mol. Neurobiol. 52, 101–114. doi: 10.1007/s12035-014-8847-x
Duce, J. A., Tsatsanis, A., Cater, M. A., James, S. A., Robb, E., Wikhe, K., et al. (2010).
An iron-export ferroxidase activity of APP is inhibited by zinc in Alzheimer’s
disease. Cell 142, 857–867. doi: 10.1016/j.cell.2010.08.014
Duck, K. A., Simpson, I. A., and Connor, J. R. (2017). Regulatory mechanisms for
iron transport across the blood-brain barrier. Biochem. Biophys. Res. Commun.
494, 70–75. doi: 10.1016/j.bbrc.2017.10.083
Dutra, F. F., and Bozza, M. T. (2014). Heme on innate immunity and inflammation.
Front. Pharmacol. 5:115. doi: 10.3389/fphar.2014.00115
Dziuba, N., and Lindahl, P. A. (2018). Low-molecular-mass iron in healthy blood
plasma is not predominately ferric citrate. Metallomics 10, 802–817. doi: 10.
1039/c8mt00055g
Feng, H., and Stockwell, B. R. (2018). Unsolved mysteries: how does lipid
peroxidation cause ferroptosis? PLoS Biol. 16:e2006203. doi: 10.1371/journal.
pbio.2006203
Friedmann Angeli, J. P., Schneider, M., Proneth, B., Tyurina, Y. Y., Tyurin, V. A.,
Hammond, V. J., et al. (2014). Inactivation of the ferroptosis regulator Gpx4
triggers acute renal failure in mice. Nat. Cell Biol. 16, 1180–1191. doi: 10.1038/
ncb3064
Gaasch, J. A., Lockman, P. R., Geldenhuys, W. J., Allen, D. D., and Van Der Schyf,
C. J. (2007). Brain iron toxicity: differential responses of astrocytes, neurons,
and endothelial cells. Neurochem. Res. 32, 1196–1208. doi: 10.1007/s11064-007-
9290-4
Galea, J., Cruickshank, G., Teeling, J. L., Boche, D., Garland, P., Perry, V. H., et al.
(2012). The intrathecal CD163-haptoglobin-hemoglobin scavenging system in
subarachnoid hemorrhage. J. Neurochem. 121, 785–792. doi: 10.1111/j.1471-
4159.2012.07716.x
Gamez, A., Carbonell, T., and Rama, R. (2003). Does nitric oxide contribute to
iron-dependent brain injury after experimental cerebral ischaemia? J. Physiol.
Biochem. 59, 249–254. doi: 10.1007/BF03179881
Gao, G., Zhang, N., Wang, Y., Wu, Q., Yu, P., Shi, Z., et al. (2017). Mitochondrial
ferritin protects hydrogen peroxide-induced neuronal cell damage. Aging Dis.
8, 458–470. doi: 10.14336/AD.2016.1108
Gao, M., Monian, P., Quadri, N., Ramasamy, R., and Jiang, X. (2015).
Glutaminolysis and transferrin regulate ferroptosis. Mol. Cell 59, 298–308. doi:
10.1016/j.molcel.2015.06.011
García-Yébenes, I., García-Culebras, A., Peña-Martínez, C., Fernández-López, D.,
Díaz-Guzmán, J., Negredo, P., et al. (2018). Iron overload exacerbates the risk
Frontiers in Neuroscience | www.frontiersin.org 13 February 2019 | Volume 13 | Article 85
fnins-13-00085 February 15, 2019 Time: 19:40 # 14
DeGregorio-Rocasolano et al. The Iron Side of Stroke
of hemorrhagic transformation after tPA (tissue-type plasminogen activator)
administration in thromboembolic stroke mice. Stroke 49, 2163–2172. doi:
10.1161/STROKEAHA.118.021540
García-Yébenes, I., Sobrado, M., Moraga, A., Zarruk, J. G., Romera, V. G., Pradillo,
J. M., et al. (2012). Iron overload, measured as serum ferritin, increases brain
damage induced by focal ischemia and early reperfusion. Neurochem. Int. 61,
1364–1369. doi: 10.1016/j.neuint.2012.09.014
Garton, A. L. A., Gupta, V. P., Christophe, B. R., and Connolly, E. S. (2017).
Biomarkers of functional outcome in intracerebral hemorrhage: interplay
between clinical metrics, CD163, and ferritin. J. Stroke Cerebrovasc. Dis. 26,
1712–1720. doi: 10.1016/j.jstrokecerebrovasdis.2017.03.035
Gazzina, S., Premi, E., Zanella, I., Biasiotto, G., Archetti, S., Cosseddu, M.,
et al. (2016). Iron in frontotemporal lobar degeneration: a new subcortical
pathological pathway? Neurodegener. Dis. 16, 172–178. doi: 10.1159/000440843
Guan, H., Yang, H., Yang, M., Yanagisawa, D., Bellier, J. P., Mori, M., et al. (2017).
Mitochondrial ferritin protects SH-SY5Y cells against H2O2-induced oxidative
stress and modulates α-synuclein expression. Exp. Neurol. 291, 51–61. doi:
10.1016/j.expneurol.2017.02.001
Guirao, V., Martí-Sistac, O., DeGregorio-Rocasolano, N., Ponce, J., Dávalos, A.,
and Gasull, T. (2017). Specific rescue by ortho-hydroxy atorvastatin of cortical
GABAergic neurons from previous oxygen/glucose deprivation: role of pCREB.
J. Neurochem. 143, 359–374. doi: 10.1111/jnc.14210
Gutteridge, J. M., Richmond, R., and Halliwell, B. (1979). Inhibition of the
iron-catalysed formation of hydroxyl radicals from superoxide and of lipid
peroxidation by desferrioxamine. Biochem. J. 184, 469–472. doi: 10.1042/
bj1840469
Hadziahmetovic, M., Song, Y., Ponnuru, P., Iacovelli, J., Hunter, A., Haddad, N.,
et al. (2011). Age-dependent retinal iron accumulation and degeneration in
hepcidin knockout mice. Investig. Ophthalmol. Vis. Sci. 52, 109–118. doi: 10.
1167/iovs.10-6113
Haeger, P., Alvarez, A., Leal, N., Adasme, T., Núñez, M. T., and Hidalgo, C.
(2010). Increased hippocampal expression of the divalent metal transporter
1 (DMT1) mRNA variants 1B and +IRE and DMT1 protein after NMDA-
receptor stimulation or spatial memory training. Neurotox. Res. 17, 238–247.
doi: 10.1007/s12640-009-9096-z
Hambright, W. S., Fonseca, R. S., Chen, L., Na, R., and Ran, Q. (2017). Ablation of
ferroptosis regulator glutathione peroxidase 4 in forebrain neurons promotes
cognitive impairment and neurodegeneration. Redox Biol. 12, 8–17. doi: 10.
1016/j.redox.2017.01.021
Hamdi, A., Roshan, T. M., Kahawita, T. M., Mason, A. B., Sheftel, A. D., and
Ponka, P. (2016). Erythroid cell mitochondria receive endosomal iron by a
“kiss-and-run” mechanism. Biochim. Biophys. Acta 1863, 2859–2867. doi: 10.
1016/j.bbamcr.2016.09.008
Han, J., Plummer, J., Liu, L., Byrd, A., Aschner, M., and Erikson, K. M. (2017). The
impact of obesity on brain iron levels and α-synuclein expression is regionally
dependent. Nutr. Neurosci. doi: 10.1080/1028415X.2017.1387720 [Epub ahead
of print].
Hanson, L. R., Roeytenberg, A., Martinez, P. M., Coppes, V. G., Sweet, D. C., Rao,
R. J., et al. (2009). Intranasal deferoxamine provides increased brain exposure
and significant protection in rat ischemic stroke. J. Pharmacol. Exp. Ther. 330,
679–686. doi: 10.1124/jpet.108.149807
Hatakeyama, T., Okauchi, M., Hua, Y., Keep, R. F., and Xi, G. (2013). Deferoxamine
reduces neuronal death and hematoma lysis after intracerebral hemorrhage in
aged rats. Transl. Stroke Res. 4, 546–553. doi: 10.1007/s12975-013-0270-5
He, Y., Karabiyikoglu, M., Hua, Y., Keep, R. F., and Xi, G. (2012). Ischemic
preconditioning attenuates brain edema after experimental intracerebral
hemorrhage. Transl. Stroke Res. 3, 180–187. doi: 10.1007/s12975-012-0171-z
Heidari, M., Johnstone, D. M., Bassett, B., Graham, R. M., Chua, A. C. G., House,
M. J., et al. (2016). Brain iron accumulation affects myelin-related molecular
systems implicated in a rare neurogenetic disease family with neuropsychiatric
features. Mol. Psychiatry 21, 1599–1607. doi: 10.1038/mp.2015.192
Helal, G. K. (2008). Systemic administration of Zn2+during the reperfusion phase
of transient cerebral ischaemia protects rat hippocampus against iron-catalysed
postischaemic injury. Clin. Exp. Pharmacol. Physiol. 35, 775–781. doi: 10.1111/
j.1440-1681.2007.04858.x
Hofmeijer, J., and Van Putten, M. J. (2012). Ischemic cerebral damage: an appraisal
of synaptic failure. Stroke 43, 607–615. doi: 10.1161/STROKEAHA.111.632943
Huang, H., Chen, J., Lu, H., Zhou, M., Chai, Z., and Hu, Y. (2017). Iron-induced
generation of mitochondrial ROS depends on AMPK activity. BioMetals 30,
623–628. doi: 10.1007/s10534-017-0023-0
Huang, S., Du, F., Li, L., Liu, Y., Liu, Y., Zhang, C., et al. (2014).
Angiotensin II inhibits uptake of transferrin-bound iron but not non-
transferrin-bound iron by cultured astrocytes. Neuropeptides 48, 161–166. doi:
10.1016/j.npep.2014.04.001
Hvidberg, V., Maniecki, M. B., Jacobsen, C., Højrup, P., Møller, H. J., and
Moestrup, S. K. (2005). Identification of the receptor scavenging hemopexin-
heme complexes. Blood 106, 2572–2579. doi: 10.1182/blood-2005-03-1185
Jaffer, H., Adjei, I. M., and Labhasetwar, V. (2013). Optical imaging to map
blood-brain barrier leakage. Sci. Rep. 3:3117. doi: 10.1038/srep03117
Jahanshad, N., Kohannim, O., Hibar, D. P., Stein, J. L., McMahon, K. L., de
Zubicaray, G. I., et al. (2012). Brain structure in healthy adults is related to
serum transferrin and the H63D polymorphism in the HFE gene. Proc. Natl.
Acad. Sci. 109, E851–E859. doi: 10.1073/pnas.1105543109
Jeney, V., Eaton, J. W., Balla, G., and Balla, J. (2013). Natural history of the bruise:
formation, elimination, and biological effects of oxidized hemoglobin. Oxid.
Med. Cell. Longev. 2013:703571. doi: 10.1155/2013/703571
Ji, C., and Kosman, D. J. (2015). Molecular mechanisms of non-transferrin-
bound and transferring-bound iron uptake in primary hippocampal neurons.
J. Neurochem. 133, 668–683. doi: 10.1111/jnc.13040
Karatas, H., Eun Jung, J., Lo, E. H., and van Leyen, K. (2018). Inhibiting 12/15-
lipoxygenase to treat acute stroke in permanent and tPA induced thrombolysis
models. Brain Res. 1678, 123–128. doi: 10.1016/j.brainres.2017.10.024
Karuppagounder, S. S., Alin, L., Chen, Y., Brand, D., Bourassa, M. W., Dietrich, K.,
et al. (2018). N-acetylcysteine targets 5 lipoxygenase-derived, toxic lipids and
can synergize with PGE 2 to inhibit ferroptosis and improve outcomes following
hemorrhagic stroke in mice. Ann. Neurol. 84, 854–872. doi: 10.1002/ana.25356
Kaur, C., and Ling, E. A. (1995). Transient expression of transferrin receptors
and localisation of iron in amoeboid microglia in postnatal rats. J. Anat. 186,
165–173.
Kawabata, H. (2018). Transferrin and transferrin receptors update. Free Radic. Biol.
Med. doi: 10.1016/j.freeradbiomed.2018.06.037 [Epub ahead of print].
Kell, D. B. (2009). Iron behaving badly: inappropriate iron chelation as a major
contributor to the aetiology of vascular and other progressive inflammatory and
degenerative diseases. BMC Med. Genomics 2:2. doi: 10.1186/1755-8794-2-2
Khan, A. I., Liu, J., and Dutta, P. (2018). Iron transport kinetics through blood-
brain barrier endothelial cells. Biochim. Biophys. Acta Gen. Subj. 1862, 1168–
1179. doi: 10.1016/j.bbagen.2018.02.010
Khan, M., Sekhon, B., Jatana, M., Giri, S., Gilg, A. G., Sekhon, C., et al. (2004).
Administration of N-Acetylcysteine after focal cerebral ischemia protects brain
and reduces inflammation in a rat model of experimental stroke. J. Neurosci.
Res. 76, 519–527. doi: 10.1002/jnr.20087
Klohs, J., Steinbrink, J., Bourayou, R., Mueller, S., Cordell, R., Licha, K., et al. (2009).
Near-infrared fluorescence imaging with fluorescently labeled albumin: a novel
method for non-invasive optical imaging of blood-brain barrier impairment
after focal cerebral ischemia in mice. J. Neurosci. Methods 180, 126–132. doi:
10.1016/j.jneumeth.2009.03.002
Kumar, N., Rizek, P., Sadikovic, B., Adams, P. C., and Jog, M. (2016). Movement
disorders associated with hemochromatosis. Can. J. Neurol. Sci. 43, 801–808.
doi: 10.1017/cjn.2016.286
Kumar, S., Sheokand, N., Mhadeshwar, M. A., Raje, C. I., and Raje, M. (2012).
Characterization of glyceraldehyde-3-phosphate dehydrogenase as a novel
transferrin receptor. Int. J. Biochem. Cell Biol. 44, 189–199. doi: 10.1016/j.biocel.
2011.10.016
Latunde-Dada, G. O. (2017). Ferroptosis: role of lipid peroxidation, iron and
ferritinophagy. Biochim. Biophys. Acta Gen. Subj. 1861, 1893–1900. doi: 10.
1016/j.bbagen.2017.05.019
LeBlanc, R. H., Chen, R., Selim, M. H., and Hanafy, K. A. (2016). Heme
oxygenase-1-mediated neuroprotection in subarachnoid hemorrhage via
intracerebroventricular deferoxamine. J. Neuroinflammation 13:244. doi: 10.
1186/s12974-016-0709-1
Leclerc, J. L., Santiago-Moreno, J., Dang, A., Lampert, A. S., Cruz, P. E., Rosario,
A. M., et al. (2018). Increased brain hemopexin levels improve outcomes after
intracerebral hemorrhage. J. Cereb. Blood Flow Metab. 38, 1032–1046. doi:
10.1177/0271678X16679170
Frontiers in Neuroscience | www.frontiersin.org 14 February 2019 | Volume 13 | Article 85
fnins-13-00085 February 15, 2019 Time: 19:40 # 15
DeGregorio-Rocasolano et al. The Iron Side of Stroke
Lee, F. H. F., Su, P., Xie, Y. F., Wang, K. E., Wan, Q., and Liu, F. (2016). Disrupting
GluA2-GAPDH interaction affects axon and dendrite development. Sci. Rep.
6:30458. doi: 10.1038/srep30458
Lei, P., Ayton, S., Finkelstein, D. I., Spoerri, L., Ciccotosto, G. D., Wright, D. K.,
et al. (2012). Tau deficiency induces parkinsonism with dementia by impairing
APP-mediated iron export. Nat. Med. 18, 291–295. doi: 10.1038/nm.2613
Leitner, D. F., and Connor, J. R. (2012). Functional roles of transferrin in the brain.
Biochim. Biophys. Acta Gen. Subj. 1820, 393–402. doi: 10.1016/j.bbagen.2011.
10.016
Lewerenz, J., Ates, G., Methner, A., Conrad, M., and Maher, P. (2018). Oxytosis /
ferroptosis —( re- ) emerging roles for oxidative cell death in diseases of the
central nervous system. Front. Neurosci. 12:214. doi: 10.3389/fnins.2018.00214
Li, J. Y., Paragas, N., Ned, R. M., Qiu, A., Viltard, M., Leete, T., et al. (2009).
Scara5 Is a ferritin receptor mediating non-transferrin iron delivery. Dev. Cell
16, 35–46. doi: 10.1016/j.devcel.2008.12.002
Li, L., Fang, C. J., Ryan, J. C., Niemi, E. C., Lebron, J. A., Bjorkman, P. J., et al.
(2010). Binding and uptake of H-ferritin are mediated by human transferrin
receptor-1. Proc. Natl. Acad. Sci. 107, 3505–3510. doi: 10.1073/pnas.0913
192107
Li, L., Hao, Y., Zhao, Y., Wang, H., Zhao, X., Jiang, Y., et al. (2018). Ferroptosis
is associated with oxygen- glucose deprivation / reoxygenation- induced
Sertoli cell death. Int. J. Mol. Med. 41, 3051–3062. doi: 10.3892/ijmm.2018.
3469
Li, Q., Han, X., Lan, X., Gao, Y., Wan, J., Durham, F., et al. (2017). Inhibition
of neuronal ferroptosis protects hemorrhagic brain. JCI Insight 2:e90777. doi:
10.1172/jci.insight.90777
Li, Y., Yang, H., Ni, W., and Gu, Y. (2017). Effects of deferoxamine on blood-brain
barrier disruption after subarachnoid hemorrhage. PLoS One 12:e0172784. doi:
10.1371/journal.pone.0172784
Linkermann, A., Skouta, R., Himmerkus, N., Mulay, S. R., Dewitz, C., De Zen, F.,
et al. (2014). Synchronized renal tubular cell death involves ferroptosis. Proc.
Natl. Acad. Sci. 111, 16836–16841. doi: 10.1073/pnas.1415518111
Liu, R., Cao, S., Hua, Y., Keep, R. F., Huang, Y., and Xi, G. (2017). CD163
expression in neurons after experimental intracerebral hemorrhage. Stroke 48,
1369–1375. doi: 10.1161/STROKEAHA.117.016850
Lo, A. C. Y., Cheung, A. K. H., Hung, V. K. L., Yeung, C. M., He, Q. Y., Chiu, J. F.,
et al. (2007). Deletion of aldose reductase leads to protection against cerebral
ischemic injury. J. Cereb. Blood Flow Metab. 27, 1496–1509. doi: 10.1038/sj.
jcbfm.9600452
Luck, A. N., and Mason, A. B. (2012). Transferrin-mediated cellular iron delivery.
Curr. Top. Membr. 69, 3–35. doi: 10.1016/B978-0-12-394390-3.00001-X
Ma, B., Day, J. P., Phillips, H., Slootsky, B., Tolosano, E., and Doré, S. (2016).
Deletion of the hemopexin or heme oxygenase-2 gene aggravates brain
injury following stroma-free hemoglobin-induced intracerebral hemorrhage.
J. Neuroinflammation 13, 1–12. doi: 10.1186/s12974-016-0490-1
Ma, J., Li, F., Gan, Z., Yu, Z., Bao, X., Shen, Y., et al. (2018). Different characteristics
of hepcidin expression in IL-6 + / + and IL- 6 - / - neurons and astrocytes
treated with lipopolysaccharides. Neurochem. Res. 43, 1624–1630. doi: 10.1007/
s11064-018-2577-9
Mancias, J. D., Vaites, L. P., Nissim, S., Biancur, D. E., Kim, A. J., Wang, X.,
et al. (2015). Ferritinophagy via NCOA4 is required for erythropoiesis and
is regulated by iron dependent HERC2-mediated proteolysis. eLife 4, 1–19.
doi: 10.7554/eLife.10308
Man-man, X. U., Jun, W., and Jun-xia, X. I. E. (2017). Regulation of iron
metabolism by hypoxia-inducible factors. Sheng Li Xue Bao 69, 598–610.
Marro, S., Chiabrando, D., Messana, E., Stolte, J., Turco, E., Tolosano, E., et al.
(2010). Heme controls ferroportin1 (FPN1) transcription involving Bach1, Nrf2
and a MARE/ARE sequence motif at position -7007 of the FPN1 promoter.
Haematologica 95, 1261–1268. doi: 10.3324/haematol.2009.020123
Mayor, D., and Tymianski, M. (2018). Neurotransmitters in the mediation of
cerebral ischemic injury. Neuropharmacology 134, 178–188. doi: 10.1016/j.
neuropharm.2017.11.050
McCarthy, R. C., and Kosman, D. J. (2014). Glial cell ceruloplasmin and hepcidin
differentially regulate iron efflux from brain microvascular endothelial cells.
PLoS One 9:e89003. doi: 10.1371/journal.pone.0089003
McCarthy, R. C., Park, Y.-H., and Kosman, D. J. (2014). sAPP modulates iron
efflux from brain microvascular endothelial cells by stabilizing the ferrous iron
exporter ferroportin. EMBO Rep. 15, 809–815. doi: 10.15252/embr.201338064
McCarthy, R. C., Sosa, J. C., Gardeck, A. M., Baez, A. S., Lee, C.-H., and Wessling-
Resnick, M. (2018). Inflammation-induced iron transport and metabolism by
brain microglia. J. Biol. Chem. 293, 7853–7863. doi: 10.1074/jbc.RA118.001949
Mehdiratta, M., Kumar, S., Hackney, D., Schlaug, G., and Selim, M. (2008).
Association between serum ferritin level and perihematoma edema volume
in patients with spontaneous intracerebral hemorrhage. Stroke 39, 1165–1170.
doi: 10.1161/STROKEAHA.107.501213
Mehta, S. H., Webb, R. C., Ergul, A., Tawfik, A., and Dorrance, A. M. (2004).
Neuroprotection by tempol in a model of iron-induced oxidative stress in acute
ischemic stroke. Am. J. Physiol. Regul. Integr. Comp. Physiol. 286, R283–R288.
doi: 10.1152/ajpregu.00446.2002
Millan, M., Sobrino, T., Castellanos, M., Nombela, F., Arenillas, J. F., Riva, E.,
et al. (2007). Increased body iron stores are associated with poor outcome after
thrombolytic treatment in acute stroke. Stroke 38, 90–95. doi: 10.1161/01.STR.
0000251798.25803.e0
Millerot, E., Prigent-Tessier, A. S., Bertrand, N. M., Faure, P. J. C., Mossiat, C. M.,
Giroud, M. E., et al. (2005). Serum ferritin in stroke: a marker of increased
body iron stores or stroke severity? J. Cereb. Blood Flow Metab. 25, 1386–1393.
doi: 10.1038/sj.jcbfm.9600140
Millerot-Serrurot, E., Bertrand, N., Mossiat, C., Faure, P., Prigent-Tessier, A.,
Garnier, P., et al. (2008). Temporal changes in free iron levels after
brain ischemia. Relevance to the timing of iron chelation therapy
in stroke. Neurochem. Int. 52, 1442–1448. doi: 10.1016/j.neuint.2008.
04.002
Morris, G., Berk, M., Carvalho, A. F., Maes, M., Walker, A. J., and Puri, B. K.
(2018). Why should neuroscientists worry about iron? The emerging role of
ferroptosis in the pathophysiology of neuroprogressive diseases. Behav. Brain
Res. 341, 154–175. doi: 10.1016/j.bbr.2017.12.036
Muñoz, P., Humeres, A., Elgueta, C., Kirkwood, A., Hidalgo, C., and Núñez, M. T.
(2011). Iron mediates N-Methyl-D-aspartate receptor-dependent stimulation
of calcium-induced pathways and hippocampal synaptic plasticity. J. Biol.
Chem. 286, 13382–13392. doi: 10.1074/jbc.M110.213785
Nagy, Z., and Nardai, S. (2017). Cerebral ischemia/repefusion injury: from bench
space to bedside. Brain Res. Bull. 134, 30–37. doi: 10.1016/j.brainresbull.2017.
06.011
Nakamura, T., Keep, R. F., Hua, Y., Schallert, T., Hoff, J. T., and Xi, G. (2004).
Deferoxamine-induced attenuation of brain edema and neurological deficits
in a rat model of intracerebral hemorrhage. J. Neurosurg. 100, 672–678. doi:
10.3171/jns.2004.100.4.0672
Nandar, W., and Connor, J. R. (2011). HFE gene variants affect iron in the brain.
J. Nutr. 141, 729S–739S. doi: 10.3945/jn.110.130351
Nicolas, G., Bennoun, M., Devaux, I., Beaumont, C., Grandchamp, B., Kahn, A.,
et al. (2001). Lack of hepcidin gene expression and severe tissue iron overload
in upstream stimulatory factor 2 (USF2) knockout mice. Proc. Natl. Acad. Sci.
98, 8780–8785. doi: 10.1073/pnas.151179498
Nicolas, G., Bennoun, M., Porteu, A., Mativet, S., Beaumont, C., Grandchamp, B.,
et al. (2002a). Severe iron deficiency anemia in transgenic mice expressing liver
hepcidin. Proc. Natl. Acad. Sci. 99, 4596–4601.
Nicolas, G., Chauvet, C., Viatte, L., Danan, J. L., Bigard, X., Devaux, I., et al. (2002b).
The gene encoding the iron regulatory peptide hepcidin is regulated by anemia,
hypoxia, and inflammation. J. Clin. Invest. 110, 1037–1044.
Ottestad-Hansen, S., Hu, Q. X., Follin-Arbelet, V. V., Bentea, E., Sato, H.,
Massie, A., et al. (2018). The cystine-glutamate exchanger (xCT, Slc7a11) is
expressed in significant concentrations in a subpopulation of astrocytes in the
mouse brain. Glia 66, 951–970. doi: 10.1002/glia.23294
Park, U. J., Lee, Y. A., Won, S. M., Lee, J. H., Kang, S. H., Springer, J. E.,
et al. (2011). Blood-derived iron mediates free radical production and
neuronal death in the hippocampal CA1 area following transient forebrain
ischemia in rat. Acta Neuropathol. 121, 459–473. doi: 10.1007/s00401-010-
0785-8
Pelizzoni, I., Macco, R., Morini, M. F., Zacchetti, D., Grohovaz, F., and Codazzi, F.
(2011). Iron handling in hippocampal neurons: activity-dependent iron entry
and mitochondria-mediated neurotoxicity. Aging Cell 10, 172–183. doi: 10.
1111/j.1474-9726.2010.00652.x
Pelizzoni, I., Zacchetti, D., Smith, C. P., Grohovaz, F., and Codazzi, F. (2012).
Expression of divalent metal transporter 1 in primary hippocampal neurons:
reconsidering its role in non-transferrin-bound iron influx. J. Neurochem. 120,
269–278. doi: 10.1111/j.1471-4159.2011.07578.x
Frontiers in Neuroscience | www.frontiersin.org 15 February 2019 | Volume 13 | Article 85
fnins-13-00085 February 15, 2019 Time: 19:40 # 16
DeGregorio-Rocasolano et al. The Iron Side of Stroke
Pellegrino, R. M., Boda, E., Montarolo, F., Boero, M., Mezzanotte, M., Saglio, G.,
et al. (2016). Transferrin receptor 2 dependent alterations of brain iron
metabolism affect anxiety circuits in the mouse. Sci. Rep. 6:30725. doi: 10.1038/
srep30725
Perez de la Ossa, N., Sobrino, T., Silva, Y., Blanco, M., Millan, M., Gomis, M., et al.
(2010). Iron-related brain damage in patients with intracerebral hemorrhage.
Stroke 41, 810–813. doi: 10.1161/STROKEAHA.109.570168
Peters, D. G., Purnell, C. J., Haaf, M. P., Yang, Q. X., Connor, J. R., and
Meadowcroft, M. D. (2018). Dietary lipophilic iron accelerates regional brain
iron-load in C57BL6 mice. Brain Struct. Funct. 223, 1519–1536. doi: 10.1007/
s00429-017-1565-1
Petrova, J., Manolov, V., Hadjidekova, S., Hadjiev, E., Bogov, B., Marinov, B., et al.
(2015). Is there a link between changes in levels of hepcidin and stroke? Clin.
Lab. 61, 1935–1939.
Philpott, C. C., and Ryu, M. S. (2014). Special delivery: distributing iron in the
cytosol of mammalian cells. Front. Pharmacol. 5:173. doi: 10.3389/fphar.2014.
00173
Philpott, C. C., Ryu, M. S., Frey, A., and Patel, S. (2017). Cytosolic iron chaperones:
proteins delivering iron cofactors in the cytosol of mammalian cells. J. Biol.
Chem. 292, 12764–12771. doi: 10.1074/jbc.R117.791962
Piloni, N. E., Caro, A. A., and Puntarulo, S. (2018). Iron overload prevents oxidative
damage to rat brain after chlorpromazine administration. BioMetals doi: 10.
1007/s10534-018-0104-8 [Epub ahead of print].
Raje, C. I., Kumar, S., Harle, A., Nanda, J. S., and Raje, M. (2007). The macrophage
cell surface glyceraldehyde-3-phosphate dehydrogenase is a novel transferrin
receptor. J. Biol. Chem. 282, 3252–3261. doi: 10.1074/jbc.M608328200
Ramos, P., Santos, A., Pinto, N. R., Mendes, R., Magalhães, T., and Almeida, A.
(2014). Iron levels in the human brain: a post-mortem study of anatomical
region differences and age-related changes. J. Trace Elem. Med. Biol. 28, 13–17.
doi: 10.1016/j.jtemb.2013.08.001
Rathnasamy, G., Murugan, M., Ling, E. A., and Kaur, C. (2016). Hypoxia-
induced iron accumulation in oligodendrocytes mediates apoptosis by eliciting
endoplasmic reticulum stress. Mol. Neurobiol. 53, 4713–4727. doi: 10.1007/
s12035-015-9389-6
Ravasi, G., Pelucchi, S., Buoli Comani, G., Greni, F., Mariani, R., Pelloni, I.,
et al. (2018). Hepcidin regulation in a mouse model of acute hypoxia. Eur. J.
Haematol. 100, 636–643. doi: 10.1111/ejh.13062
Recalcati, S., Gammella, E., Buratti, P., and Cairo, G. (2017). Molecular regulation
of cellular iron balance. IUBMB Life 69, 389–398. doi: 10.1002/iub.1628
Righy, C., Bozza, M. T., Oliveira, M. F., and Bozza, F. A. (2016). Molecular, cellular
and clinical aspects of intracerebral hemorrhage: are the enemies within? Curr.
Neuropharmacol. 14, 392–402. doi: 10.2174/1570159X14666151230110058
Righy, C., Turon, R., de Freitas, G., Japiassu, A. M., Faria Neto, H. C. C., Bozza, M.,
et al. (2018). Hemoglobin metabolism by-products are associated with an
inflammatory response in patients with hemorrhagic stroke. Rev. Bras. Ter.
Intens. 30, 21–27. doi: 10.5935/0103-507x.20180003
Sakamoto, K., Suzuki, T., Takahashi, K., Koguchi, T., Hirayama, T., Mori, A.,
et al. (2018). Iron-chelating agents attenuate NMDA-Induced neuronal injury
via reduction of oxidative stress in the rat retina. Exp. Eye Res. 171, 30–36.
doi: 10.1016/j.exer.2018.03.008
Sangkhae, V., and Nemeth, E. (2017). Regulation of the iron homeostatic hormone
hepcidin. Adv. Nutr. Int. Rev. J. 8, 126–136. doi: 10.3945/an.116.013961
Sankar, S. B., Donegan, R. K., Shah, K. J., Reddi, A. R., and Wood, L. B. (2018).
Heme and hemoglobin suppress amyloid β–mediated inflammatory activation
of mouse astrocytes. J. Biol. Chem. 293, 11358–11373. doi: 10.1074/jbc.RA117.
001050
Seiler, A., Schneider, M., Förster, H., Roth, S., Wirth, E. K., Culmsee, C., et al.
(2008). Glutathione peroxidase 4 senses and translates oxidative stress into
12/15-lipoxygenase dependent- and AIF-mediated cell death. Cell Metab. 8,
237–248. doi: 10.1016/j.cmet.2008.07.005
Sheokand, N., Malhotra, H., Chauhan, A. S., Kumar, M., Chaudhary, S., Patidar, A.,
et al. (2016). Reverse overshot water-wheel retroendocytosis of apotransferrin
extrudes cellular iron. J. Cell Sci. 129, 843–853. doi: 10.1242/jcs.180356
Shin, J. A., Kim, Y. A., Kim, H. W., Kim, H. S., Lee, K. E., Kang, J. L., et al. (2018).
Iron released from reactive microglia by noggin improves myelin repair in the
ischemic brain. Neuropharmacology 133, 202–215. doi: 10.1016/j.neuropharm.
2018.01.038
Sillerova, T., Zivny, J., Vyoral, D., and Petrak, J. (2012). Nutritional hepatic iron
overload is not prevented by parenteral hepcidin substitution therapy in mice.
Br. J. Nutr. 108, 1723–1725. doi: 10.1017/S0007114512000116
Simpson, I. A., Ponnuru, P., Klinger, M. E., Myers, R. L., Devraj, K., Coe, C. L.,
et al. (2015). A novel model for brain iron uptake: introducing the concept of
regulation. J. Cereb. Blood Flow Metab. 35, 48–57. doi: 10.1038/jcbfm.2014.168
Skjorringe, T., Burkhart, A., Johnsen, K. B., and Moos, T. (2015). Divalent metal
transporter 1 (DMT1) in the brain: implications for a role in iron transport at
the blood-brain barrier, and neuronal and glial pathology. Front. Mol. Neurosci.
8:19. doi: 10.3389/fnmol.2015.00019
Slomka, A., Switoñska, M., and Zekanowska, E. (2015). Hepcidin
levels are increased in patients with acute ischemic stroke:
preliminary report. J. Stroke Cerebrovasc. Dis. 24, 1570–1576. doi:
10.1016/j.jstrokecerebrovasdis.2015.03.031
Sonnweber, T., Nachbaur, D., and Schroll, A. (2014). Hypoxia induced
downregulation of hepcidin is mediated by platelet derived growth factor BB.
Gut 63, 1951–1959. doi: 10.1136/gutjnl-2013-305317
Soria, F. N., Pérez-samartín, A., Martin, A., Gona, K. B., Llop, J., Szczupak, B., et al.
(2014). Extrasynaptic glutamate release through cystine / glutamate antiporter
contributes to ischemic damage. J. Clin. Inverstig. 124, 3645–3655. doi: 10.1172/
JCI71886
Soria, F. N., Zabala, A., Pampliega, O., Palomino, A., Miguelez, C., Ugedo, L., et al.
(2016). Cystine/glutamate antiporter blockage induces myelin degeneration.
Glia 64, 1381–1395. doi: 10.1002/glia.23011
Sterling, J., Gutthaa, S., Song, Y., Song, D., Hadziahmetovic, M., and Dunaief, J. L.
(2017). Iron importers Zip8 and Zip14 are expressed in retina and regulated
by retinal iron levels JacobHHS public access. Exp. Eye Res. 155, 15–23. doi:
10.1016/j.exer.2016.12.008
Strazielle, N., and Ghersi-Egea, J.-F. (2016). Potential pathways for CNS drug
delivery across the blood-cerebrospinal fluid barrier. Curr. Pharm. Des. 22,
4942–4958. doi: 10.2174/1381612822666160726112115
Sweeny, E. A., Singh, A. B., Chakravarti, R., Martinez-Guzman, O., Saini, A.,
Haque, M. M., et al. (2018). Glyceraldehyde 3-phosphate dehydrogenase is a
chaperone that allocates labile heme in cells. J. Biol. Chem. 293, 14557–14568.
doi: 10.1074/jbc.RA118.004169
Tan, G., Liu, L., He, Z., Sun, J., Xing, W., and Sun, X. (2016). Role of hepcidin and
its downstream proteins in early brain injury after experimental subarachnoid
hemorrhage in rats. Mol. Cell. Biochem. 418, 31–38. doi: 10.1007/s11010-016-
2730-1
Tauchenová, L., Køížová, B., Kubánek, M., Fraòková, S., Melenovskı , V.,
Tintìra, J., et al. (2016). Successful treatment of iron-overload cardiomyopathy
in hereditary hemochromatosis with deferoxamine and deferiprone. Can. J.
Cardiol. 32, 1574.e1–1574.e3. doi: 10.1016/j.cjca.2016.07.589
Tian, Y., He, Y., Song, W., Zhang, E., and Xia, X. (2017). Neuroprotective effect of
deferoxamine on N-methyl-d-aspartate-induced excitotoxicity in RGC-5 cells.
Acta Biochim. Biophys. Sin. 49, 827–834. doi: 10.1093/abbs/gmx082
Todorich, B., Zhang, X., and Connor, J. R. (2011). H-ferritin is the major source of
iron for oligodendrocytes. Glia 59, 927–935. doi: 10.1002/glia.21164
Todorich, B., Zhang, X., Slagle-Webb, B., Seaman, W. E., and Connor, J. R. (2008).
Tim-2 is the receptor for H-ferritin on oligodendrocytes. J. Neurochem. 107,
1495–1505. doi: 10.1111/j.1471-4159.2008.05678.x
Tripathi, A. K., Karmakar, S., Asthana, A., Ashok, A., Desai, V., Baksi, S., et al.
(2017). Transport of non-transferrin bound iron to the brain: implications for
Alzheimer’s disease. J. Alzheimer’s Dis. 58, 1109–1119. doi: 10.3233/JAD-170097
Truman-Rosentsvit, M., Berenbaum, D., Spektor, L., Cohen, L. A., Belizowsky-
Moshe, S., Lifshitz, L., et al. (2018). Ferritin is secreted via 2 distinct nonclassical
vesicular pathways. Blood 131, 342–352. doi: 10.1182/blood-2017-02-768580
Tuo, Q., Lei, P., Jackman, K. A., Li, X., Xiong, H., Li, X., et al. (2017). Tau-mediated
iron export prevents ferroptotic damage after ischemic stroke. Mol. Psychiatry
22, 1520–1530. doi: 10.1038/mp.2017.171
Turkmen, S., Gonenc, O. C., Karaca, Y., Mentese, A., Demir, S., Beyhun, E.,
et al. (2016). The effect of ethyl pyruvate and N -acetylcysteine on ischemia-
reperfusion injury in an experimental model of ischemic stroke. Am. J. Emerg.
Med. 34, 1804–1807. doi: 10.1016/j.ajem.2016.06.003
Uranga, R. M., and Salvador, G. A. (2018). Unraveling the burden of iron in
neurodegeneration: intersections with amyloid beta peptide pathology. Oxid.
Med. Cell. Longev. 2018:2850341. doi: 10.1155/2018/2850341
Frontiers in Neuroscience | www.frontiersin.org 16 February 2019 | Volume 13 | Article 85
fnins-13-00085 February 15, 2019 Time: 19:40 # 17
DeGregorio-Rocasolano et al. The Iron Side of Stroke
Van Dijk, B. A. C., Laarakkers, C. M. M., Klaver, S. M., Jacobs, E. M. G., Van Tits,
L. J. H., Janssen, M. C. H., et al. (2008). Serum hepcidin levels are innately
low in HFE-related haemochromatosis but differ between C282Y-homozygotes
with elevated and normal ferritin levels. Br. J. Haematol. 142, 979–985. doi:
10.1111/j.1365-2141.2008.07273.x
Van Hoecke, M., Prigent-Tessier, A., Bertrand, N., Prevotat, L., Marie, C., and
Beley, A. (2005). Apoptotic cell death progression after photothrombotic focal
cerebral ischaemia: effects of the lipophilic iron chelator 2,2’-dipyridyl. Eur. J.
Neurosci. 22, 1045–1056. doi: 10.1111/j.1460-9568.2005.04297.x
Vela, D. (2018). Hepcidin, an emerging and important player in brain iron
homeostasis. J. Transl. Med. 16:25. doi: 10.1186/s12967-018-1399-5
Wan, L., Nie, G., Zhang, J., and Zhao, B. (2012). Overexpression of human wild-
type amyloid-β protein precursor decreases the iron content and increases
the oxidative stress of neuroblastoma SH-SY5Y cells. J. Alzheimer’s Dis. 30,
523–530. doi: 10.3233/JAD-2012-111169
Wang, J., and Doré, S. (2007). Inflammation after intracerebral hemorrhage.
J. Cereb. Blood Flow Metab. 27, 894–908. doi: 10.1038/sj.jcbfm.9600403
Ward, R. J., Zucca, F. A., Duyn, J. H., Crichton, R., and Zecca, L. (2014). The
role of iron in brain ageing and neurodegenerative disorders. Lancet Neurol.
13, 1045–1060. doi: 10.1016/S1474-4422(14)70117-6
Watts, S. D., Torres-Salazar, D., Divito, C. B., and Amara, S. G. (2014). Cysteine
transport through excitatory amino acid transporter 3 (EAAT3). PLoS One
9:e109245. doi: 10.1371/journal.pone.0109245
West, A. P., Bennett, M. J., Sellers, V. M., Andrews, N. C., Enns, C. A., and
Bjorkman, P. J. (2000). Comparison of the interactions of transferrin receptor
and transferrin receptor 2 with transferrin and the hereditary hemochromatosis
protein HFE. J. Biol. Chem. 275, 38135–38138. doi: 10.1074/jbc.C000664200
White, R. S., Bhattacharya, A. K., Chen, Y., Byrd, M., McMullen, M. F., Siegel, S. J.,
et al. (2016). Lysosomal iron modulates NMDA receptor-mediated excitation
via small GTPase, Dexras1. Mol. Brain 9:38. doi: 10.1186/s13041-016-0220-8
Worthen, C. A., and Enns, C. A. (2014). The role of hepatic transferrin receptor
2 in the regulation of iron homeostasis in the body. Front. Pharmacol. 5:34.
doi: 10.3389/fphar.2014.00034
Wu, C., Zhao, W., Yu, J., Li, S., Lin, L., and Chen, X. (2018). Induction of ferroptosis
and mitochondrial dysfunction by oxidative stress in PC12 cells. Sci. Rep. 8:574.
doi: 10.1038/s41598-017-18935-1
Wu, J., Hua, Y., Keep, R. F., Nakamura, T., Hoff, J. T., and Xi, G. (2003). Iron and
iron-handling proteins in the brain after intracerebral hemorrhage. Stroke 34,
2964–2969. doi: 10.1161/01.STR.0000103140.52838.45
Xing, Y., Hua, Y., Keep, R. F., and Xi, G. (2009). Effects of deferoxamine on brain
injury after transient focal cerebral ischemia in rats with hyperglycemia. Brain
Res. 1291, 113–121. doi: 10.1016/j.brainres.2009.07.032
Xiong, X. Y., Chen, J., Zhu, W. Y., Zhao, T., Zhong, Q., Zhou, K., et al. (2015).
Serum hepcidin concentrations correlate with serum iron level and outcome
in patients with intracerebral hemorrhage. Neurol. Sci. 36, 1843–1849. doi:
10.1007/s10072-015-2266-2
Xiong, X. Y., Liu, L., Wang, F. X., Yang, Y. R., Hao, J. W., Wang, P. F., et al.
(2016). Toll-like receptor 4/MyD88-mediated signaling of hepcidin expression
causing brain iron accumulation, oxidative injury, and cognitive impairment
after intracerebral hemorrhage. Circulation 134, 1025–1038. doi: 10.1161/
CIRCULATIONAHA.116.021881
Yang, G., Hu, R., Zhang, C., Qian, C., and Luo, Q. (2016). A combination of serum
iron, ferritin and transferrin predicts outcome in patients with intracerebral
hemorrhage. Sci. Rep. 6:21970. doi: 10.1038/srep21970
Yang, L., Fan, M., Du, F., Gong, Q., Bi, Z. G., Zhu, Z. J., et al. (2012).
Hypoxic preconditioning increases iron transport rate in astrocytes. Biochim.
Biophys. Acta Mol. Basis Dis. 1822, 500–508. doi: 10.1016/j.bbadis.2011.
12.004
Yang, Y., Dong, B., Lu, J., Wang, G., and Yu, Y. (2018). Hemopexin reduces blood-
brain barrier injury and protects synaptic plasticity in cerebral ischemic rats
by promoting EPCs through the HO-1 pathway. Brain Res. 1699, 177–185.
doi: 10.1016/j.brainres.2018.08.008
You, L. H., Li, Z., Duan, X. L., Zhao, B. L., Chang, Y. Z., and Shi, Z. H. (2016).
Mitochondrial ferritin suppresses MPTP-induced cell damage by regulating
iron metabolism and attenuating oxidative stress. Brain Res. 1642, 33–42. doi:
10.1016/j.brainres.2016.03.023
Yu, J., Guo, Y., Sun, M., Li, B., Zhang, Y., and Li, C. (2009). Iron
is a potential key mediator of glutamate excitotoxicity in spinal cord
motor neurons. Brain Res. 1257, 102–107. doi: 10.1016/j.brainres.2008.
12.030
Zeng, L., Tan, L., Li, H., Zhang, Q., Li, Y., and Guo, J. (2018). Deferoxamine therapy
for intracerebral hemorrhage: a systematic review. PLoS One 13:e0193615. doi:
10.1371/journal.pone.0193615
Zhang, H., Park, J. H., Maharjan, S., Park, J. A., Choi, K. S., Park, H., et al. (2017).
Sac-1004, a vascular leakage blocker, reduces cerebral ischemia-reperfusion
injury by suppressing blood-brain barrier disruption and inflammation.
J. Neuroinflammation 14:122. doi: 10.1186/s12974-017-0897-3
Zhang, Z., Wu, Y., Yuan, S., Zhang, P., Zhang, J., Li, H., et al. (2018).
Glutathione peroxidase 4 participates in secondary brain injury through
mediating ferroptosis in a rat model of intracerebral hemorrhage. Brain Res.
1701, 112–125. doi: 10.1016/j.brainres.2018.09.012
Zhao, J., Xiang, X., Zhang, H., Jiang, D., Liang, Y., Qing, W., et al. (2018). CHOP
induces apoptosis by affecting brain iron metabolism in rats with subarachnoid
hemorrhage. Exp. Neurol. 302, 22–33. doi: 10.1016/j.expneurol.2017.
12.015
Zhao, X., Song, S., Sun, G., Zhang, J., Strong, R., Zhang, L., et al. (2011).
Cytoprotective role of haptoglobin in brain after experimental intracerebral
hemorrhage. Acta Neurochir. Suppl. 111, 107–112. doi: 10.1007/978-3-7091-
0693-8_17
Zhou, Y. F., Zhang, C., Yang, G., Qian, Z. M., Zhang, M. W., Ma, J., et al. (2017).
Hepcidin protects neuron from hemin-mediated injury by reducing iron. Front.
Physiol. 8:332. doi: 10.3389/fphys.2017.00332
Zille, M., Karuppagounder, S. S., Chen, Y., Gough, P. J., Bertin, J., Finger, J., et al.
(2017). Neuronal death after hemorrhagic stroke in vitro and in vivo shares
features of ferroptosis and necroptosis. Stroke 48, 1033–1043. doi: 10.1161/
STROKEAHA.116.015609
Conflict of Interest Statement: The authors declare that the research was
conducted in the absence of any commercial or financial relationships that could
be construed as a potential conflict of interest.
Copyright © 2019 DeGregorio-Rocasolano, Martí-Sistac and Gasull. This is an open-
access article distributed under the terms of the Creative Commons Attribution
License (CC BY). The use, distribution or reproduction in other forums is permitted,
provided the original author(s) and the copyright owner(s) are credited and that the
original publication in this journal is cited, in accordance with accepted academic
practice. No use, distribution or reproduction is permitted which does not comply
with these terms.
Frontiers in Neuroscience | www.frontiersin.org 17 February 2019 | Volume 13 | Article 85
